Healthcare M&A News, Deals & Transaction Activity

bit.bio secured $25 million in Series D funding to broaden its portfolio of human cell models and make them available to more drug discovery customers.

Transaction signal: Portfolio breadth can make standardized human cell models useful in more preclinical assays.

Labcorp completed its acquisition of Millennium Health, an accredited specialty laboratory focused on drug testing and surveillance. The closing follows the October 23 agreement. Terms were undisclosed.

Transaction signal: Combining specialty toxicology with a national lab network can widen access for clinicians monitoring medication use.

Laza Medical announced up to US$160 million in structured Series B financing led by GE HealthCare, with returning investors Unorthodox Ventures, PA MedTech and AMED. The financing supports AI-powered robotic imaging for cardiac interventions. The disclosed ceiling is not represented as immediately received cash, and the system remains under development.

Transaction signal: Strategic participation can connect development capital with the clinical workflow and imaging expertise needed for product adoption.

Agilent completed its acquisition of digital-pathology software provider Proscia for $240 million cash at closing, plus up to $30 million tied to future performance milestones. Proscia joins Agilent’s Life Sciences and Diagnostics Markets Group.

Transaction signal: Combining laboratory instruments and reagents with software can broaden a pathology platform’s recurring revenue and workflow coverage.

Lonza signed a definitive agreement to acquire five US CDMO sites and associated operations from Merck KGaA, adding bioconjugation, payload-linker and viral-vector capabilities. Lonza disclosed total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. Closing is expected in mid-2027, subject to regulatory approvals and other customary conditions; BioReliance Contract Testing Services is excluded.

Transaction signal: CDMO consolidation can combine specialized development capabilities with manufacturing scale and a broader customer network.

Thryv Therapeutics announced a $30 million Series B led by InClin, with support from existing investors. Proceeds support the Phase 2a ASPIRE-HF trial of SGK1 inhibitor THRV-1268 in heart failure, with enrollment expected in early 2027.

Capital signal: Clinical-stage capital can pair development funding with an investor’s operating expertise as programs enter proof-of-concept trials.

Vitroscope reported $7 million of combined funding: a $5 million seed round co-led by Cerberus Ventures and YZR Capital, plus $2 million in non-dilutive funding from the Research Council of Norway. Funding supports commercial rollout and development of live-tissue perfusion platforms used in drug discovery; the full $7 million is not equity-round proceeds.

Capital signal: Research-tool financing supports commercialization of platforms designed to produce more useful biological data before clinical development.

Rockwell Medical agreed to acquire Vantive’s hemodialysis concentrates, machines, water-treatment systems, related consumables and technical services for a $125 million base price, subject to adjustments, plus up to $45 million in contingent consideration. The base price is financed by two $50 million seller term loans and a $25 million convertible note issued to Vantive. Closing is expected in mid-2027, subject to regulatory approvals and other conditions.

Transaction signal: Combining dialysis products, service capabilities and manufacturing can broaden a supplier’s recurring revenue; seller financing and contingent consideration affect transaction structure.

Cinven agreed to acquire Theramex from Carlyle and PAI Partners for undisclosed consideration. The London-based specialty pharmaceutical company develops and commercialises treatments across menopause, osteoporosis, contraception and fertility in more than 80 countries. The transaction remains subject to regulatory approvals and other customary conditions.

Transaction signal: An established therapeutic platform can attract a new sponsor seeking geographic expansion and further product acquisitions.

Globus Medical announced that it completed its acquisition of Synaptive Medical, adding cranial neurosurgery planning and visualisation technology. Financial terms were not disclosed.

Transaction signal: Complementary planning and visualisation technology can extend a surgical platform beyond its existing procedural focus.

AnewHealth announced a strategic investment from Linden and a significant new investment from existing investor Nautic. AnewHealth provides pharmacy services to people with complex medical needs. The investors did not disclose stake percentages or financial terms.

Transaction signal: Additional sponsor backing gives a complex-care pharmacy platform room to expand its services and geographic reach.

Supernus Pharmaceuticals and Indivior completed their merger, forming Supernus Inc. Legacy Supernus holders received 1.5401 Indivior shares per share; former Indivior and Supernus holders own approximately 56.5% and 43.5% of the combined company. A separate $1 billion special dividend for pre-closing Indivior holders is funded by a $650 million term loan and existing cash; it is not a disclosed merger enterprise value.

Transaction signal: Combining commercial CNS portfolios can broaden product reach and cash generation; related dividend financing is part of the coordinated transaction.

Specific Biologics closed an oversubscribed US$35 million Series A led by Hatteras Venture Partners, joined by existing and new life-sciences investors. Proceeds advance its Dualase gene-editing candidate toward initial clinical biomarker proof-of-concept in C9ORF72-associated ALS.

Capital signal: Early clinical financing can support a defined proof-of-concept milestone for genetic-medicine platforms.

Repligen issued $1 billion aggregate principal amount of 0.25% convertible senior notes due 2031 on November 6. It exchanged $541.4 million principal of the new notes for $456.8 million principal of old notes and issued $458.6 million principal of new notes for cash. The exchange itself generated no cash proceeds.

Capital signal: Convertible refinancing can extend maturities and lower interest costs while adding cash for investment; aggregate note principal differs from new cash proceeds.

Pelthos and Castle Creek signed a definitive merger agreement combining marketed dermatology products with Castle Creek’s cell and gene therapy platform. Castle Creek holders will receive 5.2 million Pelthos shares at closing, with potential additional shares, up to $300 million in milestones and a share of any priority-review-voucher sale proceeds. Closing is expected by the end of Q1 2027, subject to conditions including Castle Creek stockholder approval.

Transaction signal: Biopharma combinations can connect late-stage therapeutic platforms with established commercial operations while linking additional seller consideration to clinical and commercial outcomes.

Setara completed a $90 million Series A following Jazz Pharmaceuticals’ acquisition of Actio Biosciences. The new company will advance Actio’s remaining pipeline, including the STAR-0871 TRPV4 inhibitor. Investors include Deerfield, Canaan, Droia, EcoR1, Euclidean, Regeneron Ventures and Jazz. The financing is distinct from the previously announced Jazz/Actio acquisition.

Capital signal: Financing a retained development pipeline can preserve research continuity after a strategic buyer acquires a company for its lead program.

eCapital provided a $12 million healthcare receivables facility to an unnamed US community hospital. The facility supports working capital for acute and specialty care, including payroll and medical supplies, against eligible receivables while reimbursement remains outstanding. The disclosed amount is facility capacity, not confirmation that the full amount has been drawn.

Capital signal: Receivables-backed capital can address the timing gap between clinical service delivery and reimbursement without financing a real-estate acquisition.

Merit disclosed October 29 that it acquired all remaining Solo Pace equity on October 13 for approximately $45 million in purchase consideration. Solo Pace develops temporary pacing technology for transcatheter aortic valve replacement procedures.

Transaction signal: A device maker can use an initial minority position to build familiarity before bringing a complementary technology in-house.

InTandem completed a strategic growth investment in Atlas Health, which helps providers identify and enroll patients in financial assistance programs. Management remains a significant shareholder. Terms were undisclosed.

Transaction signal: Patient affordability tools can strengthen a provider’s revenue-cycle operations while improving access to financial assistance.

Dren Bio closed an oversubscribed $350 million private financing co-led by Juvia Group and Lightspeed Venture Partners. Proceeds support late-stage development, regulatory submission and planned commercialization of investigational dibotatug, alongside broader oncology and autoimmune programs. The company did not assign a numbered financing stage in its announcement.

Capital signal: Large private rounds can fund the transition from clinical development toward commercialization while preserving capital for additional pipeline programs.

Opentrons announced a $40 million Series E led by Avego, with additional investment from BroadOak Capital Partners. Capital will support laboratory robotics, software and data infrastructure, including AI-assisted experimental execution and geographic expansion. The company’s physical laboratory platform supports pharmaceutical research and other scientific workflows.

Capital signal: Life-sciences automation capital is funding the physical execution of experiments alongside software and data capabilities.

Verisma closed senior-secured financing from Golub Capital, including a delayed-draw term loan facility. The NewSpring Capital-backed healthcare information-management business plans to support technology investment and acquisition capacity. The financing amount was not disclosed; delayed-draw capacity is distinct from cash already funded.

Capital signal: Lender support for healthcare information-management platforms can provide capital for product investment and acquisitions without representing an ownership sale.

Davion agreed to acquire Philadelphia-based Healthcare Stat Homecare for $13.5 million: $8 million cash plus $5.5 million in shares valued at $13 per share. The agreement was signed October 27 and announced October 29. Completion is expected on or before December 31, 2026, subject to the agreement’s terms.

Transaction signal: Home-based clinical services can broaden a healthcare technology company’s operating revenue and care-delivery capabilities.

HSG acquired approximately 80% of PeierTech, a medical-grade nitinol materials and precision components manufacturer. Existing management retains remaining equity and continues operations.

Transaction signal: Specialized medical materials and precision manufacturing can attract control investment where validation and production quality create barriers to entry.

Equiti acquired Lexi, adding healthcare-focused AI language interpretation to its Martti network of qualified medical interpreters. The combination is intended to connect immediate automated language support with human interpretation across patient care. Financial terms were not disclosed.

Transaction signal: Healthcare language-services acquisitions can combine automation with specialized interpreter networks while keeping clinical communication requirements central to integration.

EVERSANA acquired London-based Estima Scientific, combining health economics and outcomes research services with proprietary AI software for pharmaceutical evidence and market access.

Transaction signal: Evidence-generation services and software can strengthen pharmaceutical commercialization platforms across pricing and market access.

Ferring Pharmaceuticals signed an agreement for the proposed acquisition of Gameto, adding reproductive-health cell-engineering capabilities. The disclosed deal value is up to $1.3825 billion, subject to development, regulatory and commercial milestones; an upfront split was not disclosed. The companies remain independent pending customary and other closing conditions.

Transaction signal: Reproductive-health acquisitions can pair emerging clinical platforms with established development and commercialization capabilities; milestone-dependent deal values differ from upfront consideration.

Kivo Health announced a $10 million Series A led by Allumia Ventures, with participation from Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures. The virtual pulmonary-care provider plans to expand clinical operations, health-plan partnerships and its technology platform. The company release is dated October 27.

Capital signal: Growth funding for home-based specialty care can support clinical delivery capacity and payer relationships alongside technology development.

Samplix completed a €25 million first closing comprising €3 million of new capital and €22 million of shareholder convertible-bond conversions. WLan holding GmbH led the financing, with major shareholders participating, to support commercial expansion of the Xdrop antibody-discovery platform. The round remains open toward a €30 million target, which is not received proceeds.

Capital signal: Shareholder debt conversions can strengthen a life-sciences platform’s balance sheet, but should be distinguished from new cash available for operating expansion.

Amanat’s Cambridge Health Group completed its acquisition of 100% of Cornerstone Healthcare from Ignite Growth. The UK specialist-care operator adds 283 beds serving patients with complex dementia, mental illness and neurological needs. Consideration comprises £71 million initial enterprise value plus up to £5 million of performance-linked deferred consideration.

Transaction signal: Cross-border consolidation in high-acuity care can expand clinical capabilities and commissioned-care relationships while retaining an established operating team.

AdeptID acquired MedSource Travelers, a travel-nurse and allied-health staffing business serving facilities nationwide. MedSource will retain its brand and existing client and clinician contacts while joining AdeptID’s healthcare staffing operations and AI matching workflows. Financial terms were not disclosed.

Transaction signal: Clinical staffing acquisitions can pair regional recruiter relationships with shared technology and a broader pool of healthcare assignments.

US WorldMeds acquired Orbus Therapeutics, adding investigational eflornithine for recurrent Grade 3 astrocytoma. Orbus is now a wholly owned subsidiary. The transaction includes an undisclosed upfront payment, potential development, regulatory and sales milestones, and tiered US net-sales royalties; amounts were not disclosed.

Transaction signal: Specialty-pharma acquisitions can combine late-stage development assets with an acquirer’s existing molecule expertise and commercialization infrastructure.

5th Century Partners announced its completed sale of Radon Medical Imaging to Leonard Green & Partners on October 27. Radon provides medical imaging equipment maintenance, repair and related services to hospitals and outpatient providers. Financial terms were not disclosed.

Transaction signal: Imaging-equipment service platforms can offer recurring demand tied to uptime, maintenance and extending the useful life of installed systems.

HealthSpan Partners, an affiliate and supporting organization of Bon Secours Mercy Health, agreed to acquire Surgery Partners at approximately $5.7 billion enterprise value. Shareholders other than Bain Capital affiliates would receive $23.50 per share in cash; Bain will roll over its stake. Closing is expected in the first quarter of 2027, subject to shareholder and regulatory approvals and other conditions.

Transaction signal: Health-system investment in outpatient surgery can combine a national physician-partnership platform with long-term capital while retaining sponsor participation.

RadNet agreed to acquire ONRAD for $350 million in cash and 5 million RadNet shares at closing, subject to adjustments, plus an earnout of up to $210 million tied to 2027 EBITDA. ONRAD supports more than 225 hospital facilities with teleradiology and professional staffing. Closing is expected in early 2027, subject to regulatory review and customary conditions.

Transaction signal: Combining radiology staffing with imaging operations and workflow technology can extend a buyer’s reach across hospital and outpatient settings.

Aptar Pharma announced its acquisition of Pulmotree, adding the Kolibri non-propellant liquid inhaler platform. The combination builds on the companies’ existing collaboration and is intended to support device development, industrialization and commercialization for complex inhaled therapies. Financial terms were not disclosed.

Transaction signal: Drug-delivery acquisitions can bring differentiated device platforms inside a larger regulatory, manufacturing and pharmaceutical-services organization.

Bolt acquired Prana Therapies in a completed stock-for-stock reverse merger. A separate $120 million private placement is expected to close October 26, 2026, with up to $60 million more available if accompanying warrants are exercised. These financing amounts are not the acquisition price.

Transaction signal: Reverse mergers can pair a clinical pipeline with a public listing and separately negotiated development capital.

Star Therapeutics announced a $200 million private financing co-led by OrbiMed and Janus Henderson Investors. The funding supports clinical advancement of preclinical programs and further pipeline expansion.

Capital signal: Experienced biotechnology teams continue to attract private capital for the next stage of drug development.

symplr completed the refinancing first announced October 6, extending debt maturities and adding sponsor investment from Clearlake Capital Group and Charlesbank Capital Partners. The company did not disclose an aggregate transaction amount in its completion announcement.

Capital signal: Refinancings can extend liquidity and operating flexibility without representing a new change-of-control acquisition.

Hexagon Bio closed a $62 million Series C led by The Column Group, with participation from existing investors. Proceeds will support the planned first-in-human study of HEX-360 and development of additional antibody-drug conjugate payload mechanisms.

Capital signal: Venture capital continues to fund differentiated oncology platforms approaching clinical development, with value dependent on subsequent trial and regulatory outcomes.

PsychPlus announced its acquisition of Precision Psychiatric Services on October 23, adding more than 100 psychiatrists and hospital-based psychiatric care across California. Financial terms were not disclosed.

Transaction signal: Hospital-based psychiatry acquisitions can extend provider coverage while connecting clinical operations with a broader behavioral-health platform.

LGM Pharma acquired Sannova Analytical, a New Jersey contract research laboratory, adding GLP bioanalysis and specialized impurity testing to its pharmaceutical analytical services. Sannova retains its name and management team. Financial terms were not disclosed.

Transaction signal: Pharmaceutical services platforms can broaden client relationships by combining analytical testing, bioanalysis and regulatory support.

TFP Fertility Group, backed by Amulet Capital Partners, acquired Manchester Fertility Group. The addition brings a Cheadle clinic and laboratory plus fertility treatment, preservation and donor-services brands, expanding TFP’s presence in northwest England. Financial terms were not disclosed.

Transaction signal: Fertility platforms continue to add regional clinical capacity and complementary laboratory and donor services through acquisitions.

Thrive Therapies announced $7.7 million in funding led by LiveOak Ventures, with Activate Venture Partners and Charter School Growth Fund participating. The company delivers therapy, evaluations and behavioral care in schools and plans to expand markets, clinical teams and its clinical intelligence platform. The financing stage was not specified.

Capital signal: Investors are backing care-delivery models that combine clinical staffing with documentation, outcomes reporting and Medicaid reimbursement workflows.

Zai Lab completed its private placement of 11.34 million ADSs on October 27, 2026, as confirmed in its October 28 company announcement. Gross proceeds were approximately US$249.93 million and net proceeds approximately US$241.17 million, primarily supporting global development of its DLL3-targeting antibody-drug conjugate. The original financing announcement was October 22.

Capital signal: PIPE financings can fund late-stage development while remaining distinct from acquisition consideration.

Real Diagnostics, an HCAP Partners portfolio company, acquired SimplyTest, adding saliva-based periodontal testing to its molecular diagnostics offering. Financial terms were not disclosed.

Transaction signal: Specialized diagnostic menus can support laboratory expansion into adjacent provider channels.

TA agreed to take a majority stake in MedEnvision, a Belgian surgical-workflow technology company. Existing shareholders remain invested. Closing is expected in the fourth quarter of 2026, subject to conditions; financial terms were not disclosed.

Transaction signal: Operating-room efficiency and international commercial expansion remain relevant themes for MedTech investors.

Promaxo announced the initial close of its Series C and a $100 million credit facility to expand MRI-platform manufacturing and support regulatory filings. The equity amount was not disclosed; $100 million refers to the credit facility.

Capital signal: Combining equity and debt can fund commercialization while managing shareholder dilution.

Diatech Pharmacogenetics announced its acquisition of SensoQuest alongside the launch of the Labcycler PCR thermal cycler. Diatech has taken over manufacturing and development of the platform in Italy, extending its molecular-diagnostics offering beyond reagents and kits. Financial terms were not disclosed.

Transaction signal: Diagnostic suppliers can use instrument acquisitions to broaden laboratory workflow coverage and integrate hardware with existing assay capabilities.

Distalmotion entered into a senior secured term-loan facility of up to $70 million with Perceptive Advisors to support US ambulatory surgery center expansion and development of its DEXTER robotic surgery system and instruments. The facility limit should not be interpreted as cash already drawn.

Capital signal: Specialist healthcare lenders can finance MedTech commercialization and site-of-care expansion alongside product development.

Sagility announced that it acquired Chirok Health, adding clinical-documentation improvement, medical coding, coding-quality assurance and revenue-integrity capabilities. The addition broadens its technology-enabled provider-services offering.

Transaction signal: Healthcare operations platforms are acquiring specialized expertise that connects clinical documentation with reimbursement and revenue-cycle performance.

INTEGRIS Health signed a definitive agreement to become part of Risant Health, subject to regulatory approvals. The Oklahoma system would be Risant's third health-system addition and retain its brand and leadership. Financial terms were not disclosed.

Transaction signal: Nonprofit health-system combinations can bring capital and value-based-care capabilities while preserving local operations.

Renovus announced a strategic partnership with Aspire Home Health Care, an orthopedic and traditional home-health provider serving Illinois and Wisconsin. The sponsor described Aspire as its sixth healthcare talent platform. Financial terms and the ownership percentage were not disclosed.

Transaction signal: Home-health platforms continue to attract investment around clinician capacity and care delivered at home.

Cencora signed a definitive agreement to acquire the equity interests in American Oncology Network that it does not already own. The transaction values AON at $2.4 billion enterprise value, comprising $2.3 billion at closing and up to $100 million in contingent value rights. AON includes more than 350 oncology providers across 21 states. Completion remains subject to regulatory clearance, stockholder approval and other closing conditions.

Transaction signal: The agreement expands a strategic oncology MSO platform. Potential shareholder rollover of up to 25% would reduce Cencora’s expected cash outlay; enterprise value is distinct from cash consideration.

Hackensack Meridian Health and Hunterdon Health signed a definitive agreement for Hunterdon to join the HMH network, subject to state and federal regulatory approval. HMH committed $200 million for capital projects and $30 million for Epic implementation; these are investment commitments, not a disclosed purchase price.

Transaction signal: Nonprofit system combinations can pair local governance commitments with capital and technology investment.

Trinity acquired Verix, bringing its Tovana commercial-intelligence platform and team into TrinityEDGE. The software supports pharmaceutical targeting and next-best-action workflows. Financial terms were not disclosed.

Transaction signal: Life-sciences service platforms are acquiring software that connects commercial analysis with execution.

Family Care Center completed a minority equity sale led by Apogem Capital and additional investors. Revelstoke retained its partnership while returning capital to its investors. Financial terms were not disclosed.

Capital signal: Minority capital can combine sponsor liquidity with continued funding for behavioral-health expansion.

Adocia announced a €3 million capital increase and a €4 million increase in its Vester Finance shareholder-loan agreement. The latter raises available loan capacity and should not be read as cash already drawn. The combined financing supports its development programs and cash runway.

Capital signal: Equity and expandable shareholder financing can extend development timelines without a single conventional funding round.

Ambrose Healthcare acquired 100% of AM-Pharma, adding the Phase 2-ready ilofotase alfa program for hypophosphatasia and a European base in Utrecht. AM-Pharma shareholders are entitled to up to €161 million through an upfront payment and commercialization-linked milestones, plus royalties on future sales. The upfront amount was not separately disclosed.

Transaction signal: The transaction adds a rare-disease development program while tying a portion of seller proceeds to future commercialization outcomes.

DKSH signed an agreement to acquire 100% of Dubai-headquartered NewBridge Pharmaceuticals for $390 million enterprise value. NewBridge commercializes specialty and rare-disease medicines across 14 Middle East and North Africa markets. Closing is expected by the end of the first quarter of 2027, subject to customary conditions and regulatory approvals.

Transaction signal: The agreement expands a healthcare commercial-outsourcing platform into a new region, adding market-access, medical-affairs and sales capabilities.

Tegria acquired CloudWave, combining healthcare-focused cloud hosting, cybersecurity and managed IT services. The acquisition expands the services available to healthcare organizations managing clinical applications and infrastructure. Financial terms were not disclosed; the original company announcement was October 19.

Transaction signal: Healthcare IT consolidation can combine specialized security and hosting capabilities with broader implementation and managed-service relationships.

Carenet Health acquired Invene, a healthcare-focused AI and data engineering consultancy serving payers, providers, value-based care organizations and health technology companies. Invene founder James Griffin and the team join Carenet, while Invene continues to serve its existing clients.

Transaction signal: The acquisition combines healthcare engagement operations with technical consulting, data infrastructure and AI implementation capabilities.

LUX Infusion announced its acquisition of Suite Health, a specialty infusion therapy provider based in Loveland, Colorado. The transaction expands its clinician-led infusion platform into Colorado and adds care capacity for patients receiving complex and recurring treatments.

Transaction signal: The acquisition extends a specialty-infusion platform through a regional provider with established clinical operations.

Galderma signed an agreement to acquire 100% of ZO Skin Health from shareholders including Blackstone Tactical Opportunities funds and the Obagi family for $1.5 billion enterprise value. ZO Skin Health supplies physician-dispensed skincare products and recorded approximately $330 million of net sales in the twelve months through June 2026.

Transaction signal: The agreement expands a strategic dermatology platform in physician-dispensed skincare, adding a complementary product portfolio and distribution relationships.

Labcorp entered an agreement with OPKO Health and BioReference Health to acquire selected clinical and anatomic pathology testing assets, including the 4Kscore prostate cancer test. Consideration is $722 million cash at closing, subject to adjustments, plus up to $150 million over up to ten years tied to 4Kscore revenue. Closing remains subject to customary conditions and antitrust clearance.

Transaction signal: The agreement combines laboratory consolidation with revenue-linked contingent consideration for a proprietary diagnostic test; it covers selected assets rather than all of BioReference.

Rush University System for Health and Endeavor Health announced plans to combine into a system with 12 hospitals and more than 400 care sites operating under the Rush name. Endeavor will fund an incremental $1 billion investment in community impact, academics, research and care innovation. The transaction targets an early-2027 closing following regulatory review and approval.

Transaction signal: The proposed combination joins an academic health system with a broad regional care network; the $1 billion commitment is an investment plan, not a disclosed purchase price.

Scinai announced a private placement and warrant-inducement transaction with an existing institutional investor, with approximately $4 million in expected gross proceeds before fees and expenses. Proceeds are intended to support its CDMO platform, customer programs, and immunotherapy pipeline. Closing was expected on or about October 15, subject to customary conditions.

Capital signal: The financing combines new securities with exercise of existing warrants to support development and manufacturing activities; expected proceeds exclude future exercise of newly issued warrants.

Verastem Oncology priced an underwritten offering of common stock and pre-funded warrants expected to generate approximately $250 million in gross proceeds before expenses. The company intends to fund clinical development, including VS-7375, and working capital. Closing was expected on or about October 15, subject to customary conditions.

Capital signal: The offering illustrates public-equity funding for an oncology development pipeline; it is a financing announcement rather than a change-of-control acquisition.

Undecimal Bio, a spin-out from Eleven Therapeutics, announced an $18 million seed round co-led by 4BIO Capital and IQ Capital. The funding supports targeted siRNA delivery beyond the liver, development of its DELiveri platform and expansion of its research team.

Capital signal: The round backs a delivery platform seeking to broaden the tissues and diseases that RNA medicines can address.

STERIS signed a definitive agreement to acquire Xodus Medical and related affiliates for $2.1 billion at closing, subject to adjustments, with an additional potential earnout of up to $150 million. Xodus supplies surgical-safety and patient-positioning products. Closing is expected by December 31, 2026, subject to customary conditions and regulatory approvals.

Transaction signal: The agreement expands a strategic buyer’s surgical-consumables portfolio; the approximately $300 million anticipated tax benefit is separate from the contractual purchase price.

R&S Holdings acquired Pennsylvania-based Innovo Detox, a substance use disorder treatment provider. The acquisition adds a clinical operation to the behavioral health organization behind Project Chesapeake and Recovery Network. The public announcement reports a completed sale without disclosing consideration.

Transaction signal: The transaction adds geographic coverage and treatment capacity to a regional addiction-services platform.

Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing $1.65 billion of equity value. The proposed transaction adds non-opioid pain therapies, including EXPAREL and ZILRETTA, to Viatris’s innovative medicines portfolio. Completion remains subject to the transaction’s closing conditions.

Transaction signal: The agreement illustrates strategic demand for established specialty therapeutics and complementary commercial portfolios; the disclosed figure is equity value, not enterprise value.

Atrium Therapeutics signed a securities purchase agreement for approximately $50 million of common stock and pre-funded warrants. Proceeds will support its cardiac RNA therapeutics programs and other corporate purposes. Closing was expected on or about October 9, subject to customary conditions.

Capital signal: The financing supports clinical development of targeted RNA therapies without a change-of-control transaction.

bioAffinity Technologies entered a definitive agreement for a registered direct offering of common stock or pre-funded warrants and a concurrent private placement of warrants. Expected gross proceeds of approximately $4 million will support working capital, CyPath Lung sales and general corporate purposes. Closing was expected on or about October 9, subject to conditions.

Capital signal: The transaction provides commercialization and operating capital for a noninvasive lung-disease diagnostics company.

Matchpoint Therapeutics closed a $150 million Series B financing co-led by Nextech Invest and Norwest to advance its precision covalent medicines pipeline, including MPT-062, an oral T-cell modulator expected to enter clinical development in 2027.

Capital signal: The financing gives an immunology-focused biotechnology platform substantial capital to move a lead small-molecule program toward the clinic while expanding a broader pipeline of covalent medicines.

Healthcare Services Group acquired NEXDINE Hospitality, a dining and hospitality-services provider with a significant senior-living presence. Consideration includes $93.5 million upfront and potential performance-linked payments. NEXDINE retains its brand, Mansfield headquarters and leadership as a wholly owned subsidiary.

Transaction signal: The acquisition expands outsourced support services tied to senior-living and healthcare facilities, rather than ownership of healthcare real estate.

AblePay Health completed a $20 million Series A led by F-Prime, with A1 Health Ventures and .406 Ventures participating. The funding supports expansion of its patient-payment and provider-collection platform, technology development and broader health-system coverage.

Capital signal: The investment highlights capital formation around patient affordability and healthcare revenue-cycle performance.

CD&R and McKesson entered into a definitive agreement to acquire Option Care Health for $32.05 per share, reflecting an enterprise value of approximately $5.8 billion. CD&R will hold a majority interest and McKesson a minority interest at closing, which is expected in the first half of 2027.

Transaction signal: The transaction pairs sponsor capital with a strategic healthcare investor around a scaled home and alternate-site infusion platform, highlighting continued interest in moving complex therapies into lower-cost care settings.

Apheon acquired a majority stake in Hager & Meisinger Group, a global provider of premium dental instruments and workflow solutions operating under the Meisinger and Jota brands. Existing shareholders and co-CEOs retained a meaningful ownership stake.

Transaction signal: The investment gives a healthcare-focused sponsor control of a specialized dental-instrument platform with established brands, precision manufacturing capabilities, and global distribution.

Altaris completed its $600 million acquisition of Clarivate’s Life Sciences & Healthcare segment, which will operate as an independent company spanning the Cortellis and Decision Resources Group businesses.

Transaction signal: The carve-out creates a standalone life-sciences data and decision-support platform serving pharmaceutical, biotechnology, and medical-technology customers across R&D, regulatory, safety, commercialization, and market-access workflows.

Altaris completed its acquisition of Simulations Plus for $18.50 per share in cash and is combining the business with portfolio company Chemical Computing Group. Simulations Plus is now privately held and no longer trades on Nasdaq.

Transaction signal: The transaction combines two computational drug-discovery and development software platforms, expanding sponsor-backed exposure to model-informed and AI-accelerated life-sciences workflows.

Repligen completed its acquisition of BioLife Solutions, adding cell-processing tools and biopreservation technologies used across the cell and gene therapy market. BioLife stockholders received $11.25 in cash and 0.1442 Repligen shares for each BioLife share.

Transaction signal: The combination expands a bioprocessing platform into recurring cell-therapy consumables and biopreservation products embedded across commercial and clinical-stage workflows.

Multiply Labs raised a $75 million Series B led by Dr. Patrick Soon-Shiong with NantWorks, with participation from AstraZeneca and other new and returning investors, to scale robotic manufacturing systems for complex medicines.

Capital signal: The round supports automation of biologics manufacturing across cell and gene therapies, antibodies, viral vectors, and mRNA, illustrating capital formation around physical AI and advanced biomanufacturing infrastructure.

Vaxcyte priced approximately $500 million of common stock and pre-funded warrants alongside $500 million of 1.50% convertible senior notes due 2032. The concurrent offerings support vaccine development, manufacturing and launch preparation. They were expected to close October 9, subject to conditions, and are tracked here as one coordinated financing record.

Capital signal: The financing combines equity and convertible debt to fund a late-stage vaccine platform; it is a follow-on offering, not an IPO.

General Medicine raised a $120 million Series B led by Andreessen Horowitz, with participation from Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management, and BoxGroup, bringing total funding to $152 million.

Capital signal: The financing backs a nationwide healthcare commerce and navigation platform spanning medications, labs, telehealth, specialist e-consults, and selected in-person care.

KymaThera closed an $80 million Series B led by Alta Partners, with participation from Venrock, Foresite Capital, J. Wood Capital, and other investors, to advance K-1728, its pan-mutant selective PI3Kα inhibitor.

Capital signal: The financing supports a precision-medicine program approaching first-in-human development in oncology and vascular malformations, with Phase 1 dosing expected in the fourth quarter of 2026.

RougeTx launched with a $58 million Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners to advance RTX-001, a potential oral disease-modifying therapy for hereditary hemorrhagic telangiectasia, and expand its vascular-disease pipeline.

Capital signal: The financing capitalizes a new biotechnology company around a first-in-class vascular-stability approach and a defined development program in a rare inherited bleeding disorder.

WhiteLab Genomics closed a $26 million Series B led by AVP, with participation from Yaday Health, Blast Club, Omnes Capital, and Debiopharm Innovation Fund, to accelerate in vivo validation programs and international expansion.

Capital signal: The round supports an AI-enabled genomic-medicine platform focused on designing and experimentally validating delivery vehicles and programmable genetic payloads for biopharma partners.

Sensible Biotechnologies secured a $47 million financing package that includes a Series A led by Oxford Science Enterprises and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union.

Capital signal: The blended financing supports scale-up of Sensible’s cell-based mRNA platform and clinical-grade manufacturing capabilities while combining private equity capital with public non-dilutive funding.

Arboretum LifeSciences launched with $30 million in Series A financing led by F-Prime and GV, with participation from .406 Ventures, Hims & Hers, Amgen, and other investors, to expand precision medicine and clinically indicated genetic testing for common diseases.

Capital signal: The financing combines genomics, AI, healthcare-system partnerships, and clinical-research infrastructure to broaden precision medicine beyond oncology and rare disease.

Vitalize raised a $31 million Series A led by Oak HC/FT, with participation from Norwest, .406 Ventures, Constellation Ventures, Y Combinator, Rock Health Capital, and MemorialCare Innovation Fund.

Capital signal: The financing supports an AI-native hospital operations platform that unifies staffing, scheduling, patient flow, and capacity management across clinical settings.

Symmetric Health Solutions secured a strategic growth investment from Spectrum Equity, marking the healthcare supply-chain intelligence provider’s first institutional capital since its founding in 2018.

Capital signal: The investment supports product development and growth around hospital item-master data, supply-chain intelligence, revenue integrity, and value-analysis workflows.

Shionogi signed an agreement to acquire all outstanding shares of IntraBio for $2 billion upfront, adding AQNEURSA and rare-disease development capabilities. Closing is planned for November–December 2026, subject to approvals and other conditions.

Transaction signal: The planned acquisition expands a strategic pharmaceutical buyer’s rare-disease portfolio through an approved therapy and specialized development capabilities.

GE HealthCare agreed to acquire PET radiopharmaceutical manufacturer SOFIE Biosciences from Trilantic North America for $945 million in cash. The transaction is expected to close in the first half of 2027, subject to regulatory approvals and other conditions.

Transaction signal: The acquisition would add U.S. manufacturing and distribution capacity for time-sensitive PET radiopharmaceuticals and U.S. rights to the investigational FAPI-74 imaging agent.

Evident completed its acquisition of CrestOptics, an Italian developer and manufacturer of confocal and super-resolution microscopy systems for life sciences research. Financial terms were not disclosed.

Transaction signal: The combination adds specialized optical technology and manufacturing capabilities to a broader life sciences imaging platform.

Harrow completed its acquisition of worldwide rights to TYRVAYA, excluding Japan, from Viatris. Consideration includes $30 million cash at closing and up to $70 million in sales-based milestone payments.

Transaction signal: The asset acquisition broadens an ophthalmic pharmaceutical portfolio and adds an established commercial product alongside an existing dry-eye franchise.

Consano Bio completed an oversubscribed financing that exceeded its $15 million target to support clinical development of C-1101, its investigational therapy for chronic painful lumbosacral radiculopathy.

Transaction signal: The financing supports development of a clinical-stage pain program and represents capital formation rather than a change-of-control acquisition.

Samfara completed its acquisition of Chr. Olesen Synthesis, a Danish developer and manufacturer of active pharmaceutical ingredients and advanced intermediates specializing in controlled substances.

Transaction signal: The transaction gives a life sciences-focused sponsor a specialized cGMP API manufacturing platform serving pharmaceutical customers across Europe, North America, and the Middle East.

Eurofins completed its acquisition of Element Materials Technology’s North American Life Sciences Testing Services business for an enterprise value of $400 million.

Transaction signal: The acquisition adds 27 laboratories and facilities and expands Eurofins’ North American biopharma testing footprint, highlighting continued consolidation in outsourced life sciences testing infrastructure.

TransPerfect acquired Synterex, a clinical and regulatory writing consultancy serving biotechnology and pharmaceutical companies with technology-enabled development solutions.

Transaction signal: The deal expands an outsourced life sciences services platform with specialized regulatory-writing expertise and AI-assisted authoring capabilities.

Viome acquired Sōlaria Biō, adding a proprietary microbial biobank, discovery capabilities, and clinically studied synbiotics and medical foods to its precision-health platform.

Transaction signal: The acquisition combines diagnostics, microbiome data, and clinically validated products as precision-health platforms broaden from testing into condition-specific interventions.

Surmodics acquired Alta Biomed, a medical-device coating and testing services business specializing in surface technologies for vascular and other medical devices.

Transaction signal: The acquisition adds differentiated hemocompatible coating technology and analytical testing capabilities to a scaled medical-device technology platform.

SpyGlass Pharma acquired all outstanding shares of Advanced Vision Science from Santen Pharmaceutical for approximately $13 million in cash, securing intraocular-lens manufacturing capacity.

Transaction signal: The acquisition vertically integrates a critical manufacturing capability around SpyGlass’ late-stage ophthalmic drug-delivery platform while preserving supply relationships with other lens customers.

Banner Capital formed Seaway Group and entered into a definitive agreement to acquire Seaway Plastics Engineering, MME Group, and Wright Engineered Plastics, with Seventeen Capital as a strategic co-investor.

Transaction signal: The transaction creates a sponsor-backed medical-device contract manufacturing platform spanning precision plastics and engineered manufacturing capabilities.

TriGemX Bio, formerly Kallyope, raised $94 million to advance elismetrep, its oral TRPM8 channel blocker, through Phase 3 development for acute migraine.

Capital signal: The financing backs a late-stage clinical program through pivotal development and illustrates continued investor support for differentiated neurology assets with defined regulatory pathways.

Devoted Health closed $555 million of Series G primary funding as part of a $1.18 billion primary-and-secondary financing led by Advent and co-led by Temasek.

Capital signal: The large primary raise provides substantial growth capital to a scaled Medicare-focused payer and care platform while the separate secondary component provides shareholder liquidity.

Medios completed its acquisition of a 74% stake in Caesar & Loretz (Caelo) on October 1 following antitrust clearance. Caelo supplies pharmaceutical ingredients, excipients, and compounding materials to pharmacies, hospitals, and industrial customers.

Transaction signal: The majority acquisition expands a European pharmaceutical supply network and combines complementary procurement, repacking, and distribution capabilities.

Five Independence Health System hospitals and affiliated physician practices and outpatient facilities joined WVU Health System on October 1. WVU committed $800 million over five years to facilities and services; that commitment is not a disclosed purchase price.

Transaction signal: The combination expands a regional health system’s clinical footprint while tying hospital integration to a multi-year investment program.

Grindr completed its acquisition of PurposeMed on November 2, 2026. The original agreement provided for $250 million in cash and stock plus up to $70 million in contingent cash consideration. PurposeMed’s Freddie business provides telehealth for HIV prevention.

Transaction signal: The acquisition represents a major strategic expansion from a consumer platform into integrated telehealth and HIV-prevention services, using an existing digital audience to accelerate healthcare distribution.

Resonant Clinical Solutions acquired Germany-based labfish rental solutions and its U.S. and U.K. affiliates, expanding clinical-trial equipment, calibration, and ancillary-services capabilities.

Transaction signal: The transaction extends Resonant’s European footprint and adds specialized equipment and calibration capabilities supporting increasingly complex global clinical trials.

AnaCardio completed a €62.5 million Series B financing co-led by Novo Holdings and the Ljungström family office to advance AC01 through Phase 2b development in chronic advanced heart failure.

Capital signal: The round fully funds a 400-patient Phase 2b program and provides a runway toward a Phase 3-ready asset, reflecting investor appetite for clinically de-risked cardiovascular programs.

R1 Therapeutics expanded its Series A financing to $80.5 million with new investment from Samsara BioCapital to advance AP306 through a global Phase 2b program in hyperphosphatemia.

Capital signal: The extension adds capital ahead of Phase 2b data and supports a first-in-class kidney-disease program through a meaningful clinical value inflection point.

Astrocyte Pharmaceuticals completed a $9.5 million Series B financing led by DeepWork Capital to advance Phase 2 clinical development of AST-004 for concussion and traumatic brain injury.

Capital signal: The financing supports a clinical-stage neuroprotection program through ongoing Phase 2 development and follows completion of enrollment in a sports-related concussion study.

Breye Therapeutics closed an oversubscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into Phase 2 development for non-proliferative diabetic retinopathy.

Capital signal: The round provides substantial clinical-development capital for an oral retinal-disease program and supports a broader pipeline targeting retinal conditions.

Healthcare AI lab Ortet launched with a $500 million commitment from Thoreau to build compute and data infrastructure, frontier research, and patient-centered health models.

Capital signal: The unusually large launch commitment reflects the scale of capital being deployed behind healthcare AI infrastructure intended to span clinical, biological, operational, and financial data.

AstraZeneca agreed to invest $2 billion in newly issued convertible preferred equity of Summit Therapeutics alongside a clinical collaboration centered on ivonescimab combination strategies in oncology.

Capital signal: The strategic equity investment provides Summit with substantial development capital while giving AstraZeneca a significant minority economic position without acquiring control or exclusive rights to ivonescimab.

ai3Bio launched with $48 million in Series A funding led by UPMC Enterprises and Ziff Capital Partners to advance antibody and lipid-nanoparticle platforms targeting disease-causing Th17 cells in autoimmune disease.

Capital signal: The financing combines two complementary immune-reset technologies and funds IND-enabling work toward first-in-human studies.

Tiny Health closed a $33 million Series B led by B Capital to expand its microbiome intelligence platform, clinical research, practitioner education, and healthcare-partner offerings.

Capital signal: The financing supports expansion of a diagnostics and data platform from consumer testing toward broader clinical and research applications.

Aptadir Therapeutics closed a €40 million ($45 million) Seed financing led by 4BIO Capital, with participation from EXTEND and other investors, to advance its RNA inhibitor-based therapeutics pipeline for genetic conditions and cancer.

Capital signal: The sizable seed round underscores continued investor appetite for differentiated therapeutic modalities backed by translational science and clearly defined development programs.

HealthPartners and Essentia Health announced on September 29 that their boards approved an affiliation agreement to combine the nonprofit organizations. The proposed combination remains subject to regulatory approval.

Transaction signal: The agreement illustrates regional health-system consolidation aimed at coordinating care, coverage, specialty services, and technology across a broader network.

Lifecore Biomedical entered into a definitive agreement to be acquired by Webster Equity Partners in a take-private transaction valued at up to $663.7 million, including contingent milestone payments.

Transaction signal: The transaction highlights sponsor interest in specialized pharmaceutical manufacturing platforms where technical capabilities, regulatory infrastructure, and commercial-scale capacity can support long-term growth.

Great Point Partners-backed eutecma acquired Tempaid, combining reusable and larger-format pharmaceutical cold-chain shipping systems with Tempaid’s validated parcel and last-mile temperature-controlled packaging portfolio.

Transaction signal: The combination extends a sponsor-backed cold-chain platform across Europe, North America, and Asia while broadening its offering from pallet-scale systems through patient-level delivery.

TJP, backed by Renovus Capital Partners, acquired Evolution Consulting & Research, adding life-sciences market research capabilities to its value, patient-access, strategy, creative, analytics, and commercialization platform.

Transaction signal: The acquisition reflects continued consolidation among outsourced life-sciences commercialization providers as platforms broaden capabilities across the product and patient-access lifecycle.

Link Cell Therapies increased its Series A financing from $60 million to $90 million as it began clinical dosing of LNK001, its logic-gated CAR-T therapy for advanced clear cell renal cell carcinoma.

Capital signal: The $30 million financing expansion shows capital continuing to follow cell-therapy programs as they enter first-in-human development and reach clinically meaningful milestones.

Leica Biosystems, a Danaher company, completed its acquisition of StatLab Medical Products from Linden Capital Partners and Audax Private Equity, expanding its anatomic-pathology portfolio across pre-analytical consumables, equipment, staining, imaging, and digital diagnostics.

Transaction signal: The completed acquisition broadens Leica’s end-to-end pathology workflow and reinforces strategic demand for consumables and diagnostic infrastructure that sit close to recurring laboratory workflows.

Medcor entered into an agreement to join APM Group, subject to regulatory approval, combining Medcor’s onsite, mobile, telehealth, and occupational-health services with APM’s broader health and human-services platform.

Transaction signal: The transaction points to continued consolidation in employer-focused healthcare, where scaled platforms can combine onsite clinical delivery, virtual triage, and workforce-health services across large geographic footprints.

P°Motion raised a Series A led by Cobalt Capital, with participation from WME Group, Nimble Ventures, Canaan Ventures, and Soul Ventures, to expand its AI-based biomechanical assessment and movement-health platform across sports, healthcare, and consumer applications.

Capital signal: The financing reflects investor interest in healthcare-adjacent AI platforms that pair proprietary movement data with predictive analytics and have potential to expand from performance markets into broader clinical and wellness use cases.

MGA Homecare acquired Care IV Home Health’s private duty nursing division, entering Arkansas as its seventh state and expanding skilled in-home nursing services for medically complex pediatric and adult patients.

Transaction signal: The acquisition extends a scaled home-care operator into a new state through an established local platform. Geographic density, clinical staffing infrastructure, and specialized high-acuity capabilities remain important consolidation drivers in home-based care.

Rightway raised $155 million in Series E financing led by Francisco Partners, with participation from existing investors Thrive Capital and Khosla Ventures, to support the next phase of growth across its pharmacy-benefit management and care-navigation platform.

Capital signal: Large growth rounds remain available for healthcare-benefits platforms with scaled employer distribution and measurable pharmacy-spend economics. Capital can support technology investment, product expansion, and continued competition with incumbent pharmacy-benefit models.

BigHat Biosciences closed a $75 million Series C co-led by DFJ Growth and Premji Invest, bringing total funding raised to $223 million and providing capital to advance its clinical-stage AI-designed protein therapeutics pipeline and rapid protein-design platform.

Capital signal: AI-enabled drug-development platforms are attracting growth capital as programs move from discovery into the clinic. Investors are underwriting both therapeutic pipelines and the proprietary data-generation infrastructure that can improve future molecule design.

Aqua Medical closed a Series B led by Relevance Ventures to support completion of its U.S. RESTORE-1 pilot study and preparations for a planned pivotal trial of its investigational Proximal Intestinal Mucosal Ablation procedure for Type 2 diabetes.

Capital signal: Clinical-stage MedTech companies can use growth capital to bridge pilot studies, pivotal-trial preparation, regulatory work, and product development. Investors may place particular value on differentiated procedures that address large chronic-disease populations.

GoodVets acquired WellHaven Pet Health, a network of more than 40 veterinary hospitals across seven states, expanding the combined GoodVets network from 75 to 116 hospitals.

Transaction signal: Multi-site veterinary platforms continue to use acquisitions to add geographic density and clinical capacity. Scaled networks can support centralized infrastructure while preserving local hospital operations and provider relationships.

Carisk Partners acquired FirstCare Onsite, adding onsite occupational healthcare services to its workers’ compensation care-coordination and specialty clinical platform.

Transaction signal: The transaction moves Carisk further upstream toward the point of injury and illustrates how healthcare-services platforms can use M&A to connect adjacent clinical capabilities across a broader episode of care.

Kasvu Therapeutics raised €30 million in Series A financing led by Hadean Ventures, with participation from Tesi and Innovestor Life Science Fund, to advance KTX-0141 toward clinical development for neuropsychiatric disorders.

Capital signal: Specialist life-sciences investors continue to fund differentiated CNS programs when financing is tied to defined IND-enabling and early-clinical milestones.

Prevision Medicine raised $5.4 million in Seed financing led by ACE Ventures, with participation from GoHub Ventures, SICTIC, and angel investors, to accelerate commercialization of its functional precision-oncology testing platform.

Capital signal: Early-stage diagnostics capital is supporting platforms that pair clinically actionable testing with a defined commercialization path. Oncology remains a focal area for precision-medicine investment.

Basalt Health raised a $20 million Series A led by NEA, with participation from Frist Cressey Ventures and 25m Health, to expand its AI-enabled post-acute referral and admissions platform across additional health-system markets.

Capital signal: Capital continues to target healthcare workflow software that can demonstrate measurable operational improvement inside scaled provider networks. Expansion across existing enterprise customers can provide a strong commercialization base.

Ligand Pharmaceuticals entered a financing agreement to provide AvenCell Therapeutics up to $47 million to advance its next-generation CAR-T pipeline, including up to $41 million tied to royalty economics and up to $6 million of Series C financing.

Capital signal: Structured life-sciences capital can fund clinical development while giving capital providers asset-linked economics. Royalty-based structures offer an alternative to relying exclusively on conventional venture equity.

Enveda closed a $311 million Series E led by Catalio Capital Management to advance three clinical-stage medicines into later-phase development, bring additional programs into the clinic, and continue scaling its AI-native PRISM drug-discovery platform.

Capital signal: Mega-rounds are concentrating around biotechnology companies that combine proprietary discovery platforms with clinical-stage assets. Positive human data can materially expand financing capacity by reducing platform risk and providing multiple paths to value creation.

Basecamp Research raised an oversubscribed $140 million Series C led by S32, with participation from NVIDIA and other investors, to train new generations of its EDEN biological foundation models and advance a pipeline of AI-designed therapeutics toward clinical development.

Capital signal: Life-sciences AI companies are raising larger rounds as investors move beyond model development toward proprietary therapeutic pipelines. Capital intensity rises materially as computational platforms begin funding preclinical and clinical development directly.

Anaconda Biomed closed a $56 million financing round led by Omega Funds, with participation from new and existing investors, to complete its ATHENA pivotal IDE study, continue product development, and pursue global regulatory approvals for its neurovascular thrombectomy portfolio.

Capital signal: Pivotal-stage device companies can require substantial private capital to fund clinical trials, regulatory submissions, manufacturing, and portfolio development before broad commercialization. Financing depth can directly affect strategic flexibility approaching approval milestones.

UltraSight raised $24 million in Series B2 financing led by Alive HealthTech Growth Fund to expand its AI-guided cardiac imaging workflow platform across U.S. health systems and develop additional workflows for intensive-care and circulatory-support settings.

Capital signal: Growth capital is supporting AI-enabled medical-imaging platforms where regulatory clearance, clinical evidence, and health-system adoption create a foundation for commercial scale. Workflow integration can be as important as the underlying algorithm.

Copeland completed its acquisition of Dickson, a provider of environmental monitoring, compliance, and cloud-based technology for regulated healthcare and life-sciences environments. Financial terms were not disclosed.

Transaction signal: Cold-chain and compliance infrastructure can become strategically valuable as pharmaceutical, biotechnology, and healthcare customers require continuous environmental monitoring across manufacturing, storage, distribution, and patient-care settings.

Astoriom acquired Roylance Stability Storage Limited and Roylance Scientific Limited, the Glasgow-based UK operations of life-sciences stability-storage provider Sampled, expanding specialist storage and sample-management capacity.

Transaction signal: Life-sciences infrastructure buyers can create scale through acquisitions that add compliant storage capacity, technical expertise, geographic coverage, and operational resilience. Embedded quality systems and specialized facilities can be meaningful strategic assets.

ViferaXS closed a Series A financing of up to €12 million, including grant funding, led by SPRIND and Huma with participation from private investors to advance a Phase II chronic lymphocytic leukemia trial and additional oncology programs.

Capital signal: Biotechnology companies can combine private equity and non-dilutive funding to extend runway while limiting dilution. Clinical-stage oncology programs with defined trial milestones can support blended financing structures across public and private capital sources.

Zymeworks completed its previously announced acquisition of Theravance Biopharma, adding Theravance’s healthcare assets and royalty-based cash flows to Zymeworks’ biotechnology portfolio.

Transaction signal: Completion converts a previously announced strategic combination into closed ownership and reinforces the use of M&A to aggregate royalty-bearing and development-stage biotechnology assets.

Independent Pharmacy Cooperative acquired IntegralRx, combining purchasing and support resources serving independent community pharmacies and expanding access to products, services, and operating resources.

Transaction signal: Scale in pharmacy purchasing and support services can strengthen negotiating leverage and broaden member resources as independent pharmacies navigate reimbursement and operating pressure.

HighLife raised more than $90 million (€80 million) in a financing round co-led by Andera Partners, Sofinnova Partners, Supernova Invest, and Mérieux Equity Partners to advance its U.S. pivotal study and accelerate European commercialization of its transcatheter mitral-valve replacement system.

Capital signal: Structural-heart companies can require substantial growth capital to finance pivotal studies and commercialization simultaneously. Regulatory progress, specialized device platforms, and the ability to scale across U.S. and European markets can support larger private rounds.

Biolevate raised €30 million in Series A financing co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and EQT Ventures, to expand its life-sciences AI platform internationally.

Capital signal: Life-sciences software and AI platforms are attracting growth capital where enterprise adoption spans research, clinical, regulatory, and development workflows. International expansion can become a major use of proceeds once product-market fit is established.

Telix Pharmaceuticals signed an agreement to acquire 100% of ITM Isotope Technologies Munich for $1.65 billion upfront on a cash-free, debt-free basis, with up to $700 million of additional contingent consideration tied to regulatory approvals and commercial milestones.

Transaction signal: The combination would unite radiopharmaceutical development, isotope production, manufacturing, and commercial infrastructure in a more vertically integrated platform. Strategic control of isotope supply and late-stage therapeutic assets can materially influence value as radiopharma pipelines scale.

Grünenthal announced an agreement with Bayer to acquire Stivarga, an established oral oncology treatment approved in more than 90 markets, for consideration of up to €375 million.

Transaction signal: Established-product acquisitions can add immediate commercial scale and cash flow while allowing sellers to reshape portfolios around strategic priorities. Global rights, regulatory status, geographic reach, and remaining product life can materially affect asset-level transaction economics.

DexCare acquired Mila Health, an AI care-coordination company whose agents communicate with patients to support scheduling, preparation, follow-up, and multi-step care journeys.

Transaction signal: Healthcare AI platforms are using acquisitions to move from narrow scheduling tools into broader care-coordination workflows. Health-system data integration, governed automation, and the ability to complete multi-step administrative tasks can expand a platform’s strategic role with enterprise customers.

Ascend Learning acquired M7 Health, an AI-powered clinical workforce scheduling and deployment platform used by health systems, and plans to combine it with StaffGarden and Laudio across professional development, scheduling, engagement, and retention.

Transaction signal: Healthcare workforce platforms are consolidating around connected tools that address scheduling, labor deployment, professional development, and retention. Embedded health-system workflows and measurable labor-efficiency outcomes can increase strategic value as buyers assemble broader workforce-management suites.

PAR Excellence Systems acquired Terso Solutions from Promega, combining PAR’s healthcare supply-chain platform with Terso’s ultra-high-frequency RFID inventory-tracking technology for hospitals and medical facilities.

Transaction signal: Healthcare supply-chain technology is consolidating around platforms that provide real-time inventory visibility across clinical departments. RFID infrastructure, hospital integration, recurring software relationships, and measurable working-capital savings can strengthen strategic value.

Made Scientific acquired National Resilience’s 85,000-square-foot cell-therapy manufacturing facility in East Norriton, Pennsylvania. The transaction closed September 18 and was announced September 21, adding operational GMP capacity and an experienced manufacturing team.

Transaction signal: Life-sciences manufacturing acquisitions can provide immediate qualified capacity and technical personnel without the time required for a greenfield build. GMP infrastructure, regulatory readiness, manufacturing track record, and available capacity can be central strategic assets for cell-therapy CDMOs.

Angle Health announced a $600 million equity financing at a $2.7 billion valuation, consisting of a $200 million Series C led by Vitruvian Partners and a $400 million tender offer providing liquidity to existing holders.

Capital signal: Large financings can combine primary growth capital with secondary shareholder liquidity, allowing a healthcare company to fund expansion while creating partial liquidity without a change of control. Employer distribution, underwriting performance, regulatory infrastructure, and recurring premium revenue can support late-stage capital formation.

HealthEdge Investment Partners-backed Veridian Healthcare acquired the ScarScience brand and related assets from Mitchell-Vance Laboratories, adding medical-grade silicone scar sheets and gel serums to its healthcare-products portfolio.

Transaction signal: Healthcare-products platforms can use brand and asset acquisitions to broaden distribution, add adjacent categories, and leverage existing retail, e-commerce, and professional channels. Brand recognition, channel access, product margins, and regulatory positioning can shape value even without a whole-company transaction.

Novo Nordisk acquired three early-stage obesity programs from Kallyope, including the IND-ready non-incretin peptide candidate K-554 and two additional programs aimed at novel metabolic targets.

Transaction signal: Pharmaceutical buyers continue to use targeted asset acquisitions to diversify obesity pipelines beyond established incretin mechanisms. Development stage, differentiation, intellectual property, and the ability to combine new mechanisms with existing portfolios can drive strategic value.

Penelope Health announced that Thoreau and other investors committed $100 million to fund expansion of its real-time payer-policy intelligence platform, including new products and broader coverage of insurers and medical policies.

Capital signal: Capital is targeting healthcare administrative infrastructure that converts fragmented payer rules into structured, machine-readable data. Coverage breadth, workflow integration, proprietary rule normalization, and the ability to reduce prior-authorization and coverage friction can support strategic value.

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock transaction, shifting the combined company’s focus toward Marea’s clinical-stage cardioendocrine pipeline while retaining strategic optionality around Lisata’s legacy assets.

Transaction signal: Public-biotech combinations can reset a company around a new clinical pipeline while using public-market currency and governance infrastructure to support development. Post-transaction ownership, cash runway, pipeline maturity, and legacy-asset rights can materially influence transaction structure.

Lisata Therapeutics entered into a definitive purchase agreement for a $225 million private placement concurrent with its acquisition of Marea Therapeutics, with participation from RA Capital Management, Forbion, Third Rock Ventures, Perceptive Advisors, and other life-sciences investors.

Capital signal: Concurrent financings can recapitalize a public biotechnology company at the same time as a strategic combination, providing runway for the acquired pipeline and changing post-transaction ownership. Investor quality, financing terms, development milestones, and dilution are important components of the combined transaction.

Aethlon Medical entered into a definitive all-stock merger agreement with North Immunology. The combined company is expected to operate as North Immunology and trade on Nasdaq under the ticker NRTX, with a pro forma equity value of approximately $346.5 million including the concurrent private placement.

Transaction signal: The transaction illustrates how public-company mergers can provide private biotechnology companies with a public-market platform while pairing strategic combination mechanics with new institutional capital. Clinical-stage assets, cash runway, ownership structure, and contingent rights to legacy assets can all influence transaction economics.

North Immunology announced an oversubscribed private placement expected to provide approximately $180 million in gross proceeds, including the conversion of roughly $34 million of outstanding convertible notes, alongside its proposed merger with Aethlon Medical.

Capital signal: The financing shows how private placements can be structured concurrently with strategic combinations to capitalize the post-transaction company through multiple clinical milestones. The investor syndicate includes Bain Capital Life Sciences, Janus Henderson, Deep Track Capital, Longitude Capital, TCGX, and other healthcare-focused institutions.

NMS Capital partnered with management to recapitalize Endoscopy Corporation of America and concurrently acquired Medical Optics from Probo Medical, combining the businesses to form Asurgence Medical, a surgical-suite maintenance, repair, and overhaul platform.

Transaction signal: The platform formation highlights sponsor interest in outsourced medical-equipment lifecycle services. Hard-to-source parts, multi-OEM repair capabilities, recurring service demand, and relationships with hospitals, ASCs, and physician groups can support a buy-and-build strategy.

Advent International entered into a definitive agreement to invest INR 31.5 billion of primary capital in Yatharth Hospital and Trauma Care Services for an expected 24.9% minority stake. Yatharth operates nine multi-specialty hospitals with approximately 2,800 operational beds.

Transaction signal: The investment reflects private equity appetite for scaled hospital platforms where new primary capital can support organic growth and acquisitions without a full change of control. Bed capacity, regional density, clinical breadth, and expansion runway can drive sponsor interest.

MRO acquired Vyne Medical, a clinical-data intake and intelligent document-processing platform serving more than 800 hospitals. Vyne Medical converts unstructured information from paper, voice, fax, images, and electronic data into digital information for clinical and financial workflows.

Transaction signal: Healthcare data platforms are consolidating around the ability to capture, normalize, and route high-volume clinical information. Embedded hospital relationships and workflow automation can broaden a buyer’s role across the clinical-data lifecycle.

Emerald Square Ventures made a majority investment in H Clinical, a clinical-research services company with in-country teams across Latin America supporting sponsors, CROs, and research sites through staffing, patient recruitment, in-home trial support, procurement, and logistics.

Transaction signal: Life-sciences services investors continue to target specialized clinical-trial infrastructure with geographic reach and differentiated patient-access capabilities. Majority investments can fund expansion while retaining management continuity and sector expertise.

Terra Behavioral Health acquired Latitude Recovery Center in Carlsbad, California, adding partial-hospitalization and intensive-outpatient services for adults with substance use disorders and co-occurring mental-health conditions.

Transaction signal: Behavioral-health platforms continue to use acquisitions to add treatment capacity, payer contracts, and service-line depth. In SUD treatment, local referral relationships, clinical staffing, reimbursement access, and continuum-of-care coverage can be important strategic assets.

Sling Therapeutics closed a $123 million Series C led by Forbion, with participation from TPG Life Sciences Innovations and Sectoral Asset Management, to advance linsitinib through its global Phase 3 ORBIT trial in thyroid eye disease.

Capital signal: Late-stage biopharma financings continue to concentrate around programs with pivotal clinical milestones. Large private rounds can extend runway through Phase 3 development while preserving strategic optionality ahead of commercialization, partnership, or M&A.

Circle Pharma closed an oversubscribed $92.5 million Series E led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly, to advance its cyclin D1 program toward clinical development.

Capital signal: Strategic and institutional capital is continuing to fund oncology programs approaching first-in-human development. Participation from a large pharmaceutical investor can provide additional validation while financing a company through costly clinical milestones.

Anew Labs, the AI-driven drug-discovery business spun out of ByteDance, raised $290 million in its first external financing at a reported $1.5 billion valuation. Investors included HSG, IDG Capital, GL Ventures, 5Y Capital, and other institutional backers.

Capital signal: Large financings are continuing to support AI-enabled drug-discovery platforms where investors are underwriting both technology and therapeutic-development potential. Spinouts can also use external capital to establish independent governance, incentives, and strategic flexibility.

Ayble Health closed an oversubscribed $16 million Series A led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, Accomplice, and other investors to expand its virtual digestive-health clinic.

Capital signal: Virtual specialty-care platforms can attract growth capital when they combine clinical evidence, payer or employer distribution, and technology-enabled care delivery. Digestive and autoimmune care also offers opportunities to expand across chronic conditions without relying on a pure software model.

Ferry Health launched out of stealth with $9 million in seed funding from Andreessen Horowitz, Index Ventures, Avid Ventures, Layout Ventures, SV Angel, BoxGroup, Asymmetric Capital, and individual investors to build an AI healthcare personal assistant.

Capital signal: Early-stage capital continues to target AI tools that automate consumer-facing healthcare administration such as finding providers and scheduling care. Adoption will depend on workflow reliability, integration, consumer trust, and the ability to navigate fragmented healthcare systems.

Medallion acquired Andros, an NCQA-certified credentials verification organization, bringing more than one million providers across nearly 400 healthcare organizations and health plans onto a combined credentialing platform.

Transaction signal: Credentialing and provider-data platforms are consolidating around scale, automation, and unified workflows across health plans and provider organizations. Large provider datasets and embedded verification processes can deepen customer relationships and operating leverage.

Hello Patient acquired Converse Health, an AI workflow-automation company for outpatient medical practices, extending its patient-communications platform into document, chart, referral, follow-up, and payer-paperwork workflows.

Transaction signal: Healthcare AI platforms are broadening from narrow point solutions into end-to-end administrative workflow automation. Acquisitions can accelerate product expansion where complementary tools share the same provider customer base and clinical operating environment.

Renew Health + Recovery purchased many of the assets of Aware Recovery Care, including clinical models and care teams supporting in-home and virtual substance-use-disorder treatment across 11 states.

Transaction signal: Behavioral-health asset transactions can preserve clinical capacity and patient continuity while transferring operating infrastructure to a new platform. In-home SUD models may be valued for payer relationships, specialized care teams, and geographic reach.

Thatch raised $108 million in Series C funding at a $1 billion valuation from The General Partnership, Index Ventures, General Catalyst, Andreessen Horowitz, and other investors to expand its consumer-directed employer health-benefits platform.

Capital signal: Capital is flowing toward benefits platforms that shift employers from traditional group plans toward individualized healthcare budgets and plan selection. Scale, employer distribution, payments infrastructure, and regulatory complexity can create meaningful barriers to entry.

RegCell secured $66 million of additional funding, including a $44 million Series A led by Playground Global and approximately $22 million of non-dilutive funding from Japan’s Agency for Medical Research and Development.

Capital signal: The financing shows how biotechnology companies can combine venture equity with non-dilutive funding to extend runway and preserve ownership while advancing platform technology into the clinic. The capital is intended to support IND submission and autoimmune-development programs.

Evvy raised a $40 million Series B led by Catalio Capital Management to expand its women’s-health platform built around vaginal-microbiome testing, clinical care, and a growing dataset generated from more than 100,000 patients.

Capital signal: Women’s-health diagnostics can create value from the combination of proprietary testing, longitudinal data, clinical interpretation, and consumer access. Growth capital can support both care delivery and research applications built around differentiated datasets.

ReEmerge emerged from stealth after closing an oversubscribed $37 million Series A to support clinical evaluation of its Cognitive Network Restoration Therapy for chronic cognitive impairment following traumatic brain injury.

Capital signal: MedTech investors continue to fund novel neuromodulation and neuro-restoration platforms where capital is tied to first clinical studies, regulatory execution, and evidence generation. Early clinical validation can materially affect later financing and strategic options.

Seven Hills Capital-backed Spa Medicca partnered with Dr. Nicholas E. Sherock & Associates and Your Best Kept Secret Aesthetics, bringing women’s health, hormone optimization, gynecologic surgery, medical aesthetics, and wellness services onto the broader platform.

Transaction signal: Medical-aesthetics and women’s-health platforms continue to consolidate physician-led practices that combine clinical services with elective and recurring wellness offerings. Provider reputation, retention, patient acquisition, and local density can be important underwriting factors.

Addus HomeCare entered into a definitive agreement to acquire AccentCare’s personal care division outside New York for approximately $275 million, adding an estimated $280 million of annualized revenue and expanding operations across multiple states.

Transaction signal: Home-care scale remains strategically valuable where acquisitions can deepen caregiver density, referral relationships, and geographic coverage. Large personal-care transactions also highlight the importance of labor availability, reimbursement, and integration capacity in home-based services.

HopeHealth acquired Eastern Carolina Pediatric Associates, a pediatric practice serving families in Florence and Darlington Counties, South Carolina, bringing its providers, nurses, and staff into HopeHealth’s growing care network.

Transaction signal: Nonprofit provider organizations can use acquisitions to expand access and specialty coverage while preserving local clinician relationships. Pediatric practices can add referral density, continuity of care, and community presence to broader primary-care networks.

Archy raised a $50 million Series C led by JMI Equity, with participation from TCV, Entrée Capital, Bessemer Venture Partners, CRV, and Alven, to accelerate development of AI agents and expand its dental practice-management platform.

Capital signal: Dental software continues to attract growth capital where platforms combine core practice-management workflows with payments, insurance administration, and AI-enabled automation. Deep workflow integration can create durable customer relationships across independent dental practices.

Axogen completed its previously announced acquisition of BioCircuit Technologies, developer of NerveTape, the first FDA-cleared device for sutureless peripheral nerve repair.

Transaction signal: The transaction expands Axogen’s nerve-repair portfolio with an adjacent device that can leverage existing surgeon relationships and hospital contracting. MedTech buyers continue to pursue differentiated technologies that can be scaled through established commercial infrastructure.

Altas Partners and L Catterton agreed to acquire a majority stake in Fullscript from HGGC and Snapdragon Capital Partners. Fullscript supports more than 135,000 healthcare practitioners with clinical-support, laboratory, supplement, and patient-adherence tools.

Transaction signal: Sponsor interest remains strong in scaled healthcare platforms that sit inside practitioner workflows and combine software, data, clinical tools, and recurring transaction activity. Majority investments can provide seller liquidity while preserving management continuity and funding another phase of growth.

Vheda Health secured a $47 million investment from Agora, representing the healthcare analytics company’s first institutional capital and the newly formed investment firm’s inaugural transaction.

Capital signal: Growth capital is targeting healthcare analytics platforms with established payer relationships, measurable outcomes, and opportunities for product and geographic expansion. The investment also gives Vheda capital for targeted acquisitions without a change-of-control transaction.

Inspiren raised a $70 million Series C led by NewView Capital at a valuation exceeding $500 million to scale its AI-powered hardware and software platform for senior-living operators.

Capital signal: Senior-care technology is attracting growth capital where AI, sensors, workflow software, and physical infrastructure can be tied to resident safety and caregiver productivity. Scaled deployment inside care settings can support larger late-stage financings.

Danforth Health acquired Ambit, a technology-enabled solutions company providing commercial strategy, advanced analytics, and patient-identification services to rare and specialty biopharma companies.

Transaction signal: Life-sciences services platforms are combining consulting, data, technology, and commercialization capabilities across the product lifecycle. Specialized rare-disease expertise and proprietary analytics can increase strategic value as service providers broaden their client offering.

H1 acquired Defacto Health, a healthcare data company specializing in provider-network intelligence, payer networks, directory accuracy, and information on the insurance plans providers accept.

Transaction signal: Healthcare data platforms are using M&A to deepen proprietary datasets and improve payer and provider-network intelligence. Accuracy, workflow integration, and differentiated data assets can become important strategic capabilities for scaled healthtech platforms.

TwoStep Therapeutics announced an oversubscribed $62.5 million Series A led by Insight Partners and Medical Excellence Capital, with M Ventures and Pfizer Ventures joining as co-leads, alongside FDA clearance of the IND for its lead oncology program.

Capital signal: Early-stage biotech financings can expand materially when capital is paired with a clear clinical catalyst. Strategic pharmaceutical participation can provide additional validation as companies move from platform development into first-in-human studies.

VSS Capital Partners-backed Olympus Cosmetic Group acquired Gallaher Plastic Surgery & Med Spa, a Knoxville-area provider of surgical and non-surgical cosmetic procedures, marking Olympus’ entry into Tennessee.

Transaction signal: Aesthetic medicine platforms continue to expand through physician-led acquisitions that add premium brands, local market density, and complementary surgical and non-surgical services. Founder reputation, provider retention, and patient acquisition can be central to underwriting in medical aesthetics.

Labcorp acquired MLM Medical Labs, a global central and specialty laboratory provider with operations in the United States, Germany, and South Africa, expanding its clinical-trial laboratory and biomarker capabilities.

Transaction signal: Scaled laboratory buyers continue to pursue global reach, specialty testing, and clinical-trial infrastructure. Geographic laboratory networks and biomarker capabilities can deepen relationships with pharmaceutical and biotech customers across development programs.

Quva Pharma acquired a portfolio of essential sterile-compounding medications from Central Admixture Pharmacy Services following CAPS’ decision to exit the 503B outsourcing business.

Transaction signal: Portfolio transactions can shift product supply and customer relationships without a full-company acquisition. In sterile compounding, manufacturing quality, regulatory infrastructure, hospital relationships, and continuity of supply can drive strategic value.

Beacon Behavioral Partners added Prime Psychiatry and Invicta Healthcare to its physician-led network, expanding its North Texas footprint with seven additional clinic locations.

Transaction signal: Behavioral-health platforms continue to build density through physician-practice partnerships that expand access to psychiatry, TMS, Spravato, medication management, and psychotherapy. Clinical leadership and local brand continuity can support platform growth without eliminating practice autonomy.

Vitality acquired Icario, a digital-first health action company that helps health payers engage members and drive measurable population-health outcomes.

Transaction signal: Payer-facing platforms are combining engagement, behavior-change, and population-health capabilities to create broader member-experience offerings. Scale, health-plan relationships, and measurable outcomes can support strategic consolidation across payer technology.

PatientIQ raised a $30 million Series C led by Hughes & Company to expand its patient-reported outcomes intelligence platform across medical specialties, health systems, medical-device companies, and life-sciences customers.

Capital signal: Growth capital is supporting healthcare data platforms with embedded provider workflows, large patient datasets, and cross-market applications. Expansion into medical-device and life-sciences customers can broaden revenue diversification beyond provider organizations.

Clearwater Cardiovascular Consultants, a Cardiovascular Logistics partner practice, partnered with Pasco Cardiology Center to expand cardiovascular services into Pasco County, Florida.

Transaction signal: Cardiology platforms continue to build geographic density through physician-practice partnerships that preserve clinical teams while adding technology, analytics, and administrative infrastructure. Specialty scale can support broader service lines and stronger local referral networks.

HCA Healthcare sold Dominion Hospital, a freestanding behavioral-health hospital in Falls Church, Virginia, to Hill Valley Healthcare for approximately $25 million.

Transaction signal: The transaction brings a new operator into behavioral health while allowing HCA to retain a broader behavioral-health presence in Virginia. Licensed inpatient capacity, service mix, local referral relationships, and facility infrastructure can shape value in behavioral-health hospital transactions.

Fortrea entered into a definitive agreement to acquire Worldwide Clinical Trials’ Early Phase Services division for approximately $45 million in cash. The business includes a bioanalytical laboratory, a 200-bed clinical pharmacology unit, and biospecimen storage operations in Texas.

Transaction signal: The transaction adds specialized early-phase clinical development capacity and bioanalytical capabilities to Fortrea. It also illustrates strategic consolidation across outsourced life-sciences services as CROs sharpen portfolios around differentiated capabilities and scale.

Frazier Healthcare Partners completed its $490 million all-cash acquisition of MatrixCare from Resmed. MatrixCare provides cloud-based EHR and revenue-cycle software across skilled nursing, senior living, home health, hospice, and other post-acute settings.

Transaction signal: The carve-out highlights sponsor interest in vertical healthcare software with embedded workflows and recurring provider relationships. It also shows diversified healthcare companies continuing to prune portfolios while specialized investors pursue stand-alone growth platforms.

N-Power Medicine closed a $32 million Series B financing to expand its community oncology research network, deepen pharmaceutical partnerships, and continue investment in its Prospective External Control Arm platform.

Capital signal: The financing links community oncology infrastructure with drug-development services and strategic life-sciences capital. Investment in research networks and trial-enablement platforms can support both provider reach and pharmaceutical customer relationships.

Independent Pharmacy Cooperative acquired USave Pharmacy Group effective September 1, bringing the independent-pharmacy organizations together while preserving USave’s identity and member relationships.

Transaction signal: The transaction reinforces the importance of scale, purchasing leverage, operating support, and member services across independent pharmacy. Network density and shared infrastructure can help smaller pharmacy operators compete within a consolidating supply and reimbursement environment.

Scan.com raised $220 million in combined financing, including a $90 million Series C led by Noteus Partners and $130 million of debt facilities from VerisFi Capital and Atempo Growth to expand its U.S. imaging footprint.

Capital signal: The financing demonstrates how equity and debt can be combined to fund organic expansion, working capital, and acquisition capacity. Diagnostic imaging platforms may use structured capital to build geographic scale without relying on a single financing source.

Transcat acquired Southeastern Biomedical for $12.8 million in cash. Southeastern provides calibration, repair, preventive maintenance, electrical-safety inspection, and regulatory-compliance services to hospital networks and healthcare facilities.

Transaction signal: The acquisition highlights strategic interest in regulated service infrastructure surrounding medical equipment. Calibration, maintenance, compliance capabilities, and hospital relationships can create recurring demand and support broader biomedical-services platforms.

Bloom Healthcare acquired Christian Care House Calls, a Dallas-Fort Worth home-based primary-care practice serving seniors with complex health needs. The acquired providers will join Bloom while continuing to serve existing patients.

Transaction signal: Home-based primary-care consolidation can add provider capacity, referral relationships, geographic density, and access to senior populations. Buyers may value care models that extend clinical services into the home while supporting coordinated and value-based care.

Quoin Pharmaceuticals entered into a securities purchase agreement to raise up to approximately $50 million, including about $30.8 million of upfront funding and up to approximately $19.2 million from the potential exercise of accompanying warrants.

Capital signal: Late-clinical-stage specialty pharmaceutical companies can use private placements to extend development runway without a control transaction. Warrant-based structures can also create contingent follow-on capital beyond the initial funding at closing.

AusperBio closed a $120 million Series C financing to advance AHB-137 toward potential commercialization, including its Phase 3 registrational program, while supporting additional hepatitis B programs.

Capital signal: Late-stage biopharma capital is concentrating around programs approaching pivotal development and commercialization. These rounds can fund both clinical execution and the infrastructure required to prepare for launch.

Metriport raised $26 million in new funding led by Matrix, with participation from ARTIS and Y Combinator, to expand its open-source healthcare data infrastructure platform and point-of-care clinical intelligence capabilities.

Capital signal: Capital is continuing to move toward healthcare data infrastructure that can normalize fragmented records and support clinical workflows, analytics and AI applications across provider organizations.

Savista acquired ABW Medical, an ambulatory revenue cycle management company serving federally qualified health centers, medical groups, rural health providers, managed service organizations and virtual-care organizations.

Transaction signal: Revenue-cycle consolidation is extending deeper into ambulatory and non-acute settings. Specialized workflow expertise, customer relationships and embedded EHR ecosystem access can create strategic value for scaled healthcare operations platforms.

Imagenet acquired Analytica Consulting, combining Imagenet’s healthcare payer operations capabilities with Analytica’s data engineering, analytics, artificial intelligence, data science, visualization and data-governance expertise.

Transaction signal: Healthcare operations platforms are acquiring data and AI capabilities to move beyond outsourced execution toward technology-enabled decision support. Domain expertise paired with proprietary analytics can broaden strategic relevance to payer customers.

argenx completed its acquisition of Forte Biosciences at $77 per share, adding Forte’s anti-CD122 antibody FB102 to its immunology pipeline. The transaction had an approximately $2.2 billion equity value when announced in July.

Transaction signal: Biopharma buyers continue to use acquisitions to secure differentiated clinical assets and broaden therapeutic pipelines. Completion of a large cash transaction also demonstrates strategic willingness to deploy balance-sheet capital around clinically validated mechanisms.

Sword Health formally announced on September 16 that it signed an agreement to acquire Headspace, bringing Headspace’s mental-health brand and enterprise distribution into Sword’s broader AI-enabled care platform. Financial terms were not disclosed in the company announcement.

Transaction signal: The proposed combination reflects continued consolidation across digital behavioral health and virtual care. Buyers are seeking broader clinical platforms, enterprise distribution, and longitudinal member relationships rather than narrowly defined point solutions.

Globus Medical acquired Higgs Boson Health, a Duke-incubated digital healthcare experience company focused on AI-driven software for patients and providers across the episode of care.

Transaction signal: The acquisition shows a scaled medical-device company extending beyond hardware into digital workflow, patient engagement, and surgical intelligence. Strategic buyers may increasingly value software and AI capabilities that strengthen an installed clinical ecosystem.

Arintra raised a $25 million Series B led by Define Ventures to expand its AI-powered revenue-assurance platform for health systems and healthcare providers.

Capital signal: Revenue-cycle and revenue-assurance platforms continue to attract growth capital where AI can be tied to reimbursement accuracy, coding automation, denial prevention, and measurable financial outcomes for providers.

McKesson signed a definitive agreement to acquire Precision Medicine Group, a provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.

Transaction signal: The transaction reflects strategic demand for outsourced clinical-development and commercialization capabilities that deepen relationships with biopharma customers and expand higher-growth service offerings around oncology and specialty care.

Radiology Partners entered into a definitive agreement to acquire Everlight Radiology from Livingbridge, adding an international teleradiology network serving hospitals, health systems, and imaging centers across multiple markets.

Transaction signal: The deal highlights the value of radiologist capacity, geographic coverage, 24/7 subspecialty availability, and technology-enabled workflow in a market where provider shortages can make scaled teleradiology infrastructure strategically important.

Gravity 360, the parent company of Gravity Diagnostics, acquired Med-Lake Laboratory, a full-service clinical laboratory serving providers and care organizations across Georgia, Alabama, and neighboring states.

Transaction signal: Regional laboratory consolidation can add test volume, provider relationships, payer connectivity, and geographic density. Buyers may also value accredited infrastructure and the ability to spread laboratory technology and operating systems across a wider footprint.

Switchboard Health acquired Livara Health, a virtual orthopedics and musculoskeletal care platform, and said it also closed more than $5 million of equity financing to support integration and growth.

Transaction signal: The combination shows specialty-care navigation platforms moving into direct care delivery. Integrating referral management with value-based MSK care can create a broader clinical and financial proposition for health plans, providers, and risk-bearing organizations.

Airway Therapeutics closed a $50 million equity round, including previously raised SAFE capital and a Series E-2 financing, to support late-stage development of zelpultide alfa.

Capital signal: Late-stage life-sciences financings continue to fund clinical execution, manufacturing readiness, and regulatory work around priority assets. Insider participation can extend runway through major development milestones without a control transaction.

VitalCaring acquired Carter Healthcare, expanding its home health and hospice presence in Ohio and West Virginia while strengthening operations across Oklahoma, Texas, Kansas, and Missouri.

Transaction signal: Home-based care buyers continue to use acquisitions to build branch density, expand referral networks, and broaden service coverage across home health and hospice. Clinical labor, reimbursement, census quality, and local operating scale remain central considerations.

Cityblock Health signed a definitive agreement to acquire Homeward Health in an all-stock transaction, combining urban and rural value-based care models serving Medicare, Medicaid, and dual-eligible populations.

Transaction signal: The transaction highlights consolidation among value-based care platforms seeking broader geography, larger covered populations, and stronger care-delivery infrastructure. Government-program scale and risk-bearing capabilities can be meaningful strategic assets.

Cityblock Health announced a $116 million Series E led by General Catalyst alongside its agreement to acquire Homeward Health.

Capital signal: The paired financing and acquisition illustrate how growth capital can directly support strategic expansion. Scaled provider platforms may use equity financing to strengthen liquidity, fund integration, and accelerate geographic or population growth.

Radial acquired Mindful Health Solutions, expanding a behavioral-health platform focused on interventional psychiatry and multispecialty mental-health services.

Transaction signal: The transaction points to continued consolidation in specialized behavioral health, where clinic networks, clinician expertise, neuromodulation capabilities, and emerging treatment modalities can support platform strategies.

MaxQ Medical closed a $31.5 million Series A to advance an all-in-one transurethral imaging and therapy platform for prostate care.

Capital signal: MedTech financings can fund clinical programs and product development around differentiated procedural technologies. Strategic investor participation can also provide validation as companies move toward clinical and commercial milestones.

Francisco Partners entered into a definitive agreement to acquire Weave Communications, an AI-powered patient-engagement and payments platform for healthcare practices, for approximately $650 million in equity value.

Transaction signal: The take-private underscores sponsor interest in vertical healthcare software with embedded communications, payments, and revenue-cycle workflows. Practice-level distribution and recurring software relationships can support strategic value beyond standalone point solutions.

R1 entered into an agreement to acquire Humata Health, adding AI-powered prior-authorization automation to its broader revenue-cycle operating platform.

Transaction signal: Healthcare IT buyers continue to acquire workflow-specific AI capabilities where the technology can reduce administrative friction and improve reimbursement. Prior authorization is a particularly strategic workflow because it sits between providers, payers, and patient access.

Hopscotch Primary Care raised $53 million in Series D financing to expand its technology-enabled, value-based primary-care model across rural communities.

Capital signal: Growth capital remains available for care-delivery models with measurable patient engagement, payer relationships, and a path to geographic expansion. Rural healthcare platforms can use financing to add clinics, clinicians, and technology-enabled operating capacity.

Fulcrum Therapeutics and Slate Medicines entered a definitive all-stock merger agreement that would create a company focused on Slate’s next-generation migraine therapeutics. The combined company is expected to operate as Slate Medicines and trade under the ticker SLTE.

Transaction signal: The transaction illustrates how public biotech companies can use strategic combinations to reset pipelines and capital structures around higher-conviction assets. It also underscores continued investor support for focused therapeutic platforms despite uneven financing conditions.

Veritas Capital-backed Gainwell Technologies secured a nearly $6 billion debt refinancing, including a new $2.64 billion loan and maturity extensions on existing second-lien term debt and senior secured notes.

Capital signal: Large healthcare technology platforms are using the credit markets to extend maturities and preserve strategic flexibility. Debt structure, lender protections, leverage and recurring customer relationships can matter as much as equity value in capital advisory work.

Affordable Care completed a recapitalization that reduced debt by approximately $1.0 billion, provided $75 million of new capital, extended maturities to 2031 and transferred ownership to existing lenders.

Capital signal: This is a direct example of healthcare capital advisory extending beyond equity raises: balance-sheet restructurings can combine debt reduction, new-money capital, maturity extensions and ownership changes to restore financial flexibility.

Thermo Fisher Scientific completed the sale of its microbiology business to Astorg for $1.1 billion. Astorg plans to operate the business as an independent microbiology diagnostics company serving clinical, pharmaceutical, and food-safety testing markets.

Transaction signal: The carve-out highlights sponsor appetite for scaled diagnostics platforms with recurring testing workflows, installed customer relationships, and stand-alone growth potential. It also reflects portfolio optimization by diversified healthcare and life-sciences companies.

InduPro raised a $77 million Series B to advance its lead bispecific antibody-drug conjugate through first-in-human development.

Capital signal: Biotech capital continues to concentrate around programs with defined clinical milestones and syndicates that include strategic pharmaceutical investors.

Infinimmune raised a $75 million Series A to move two antibody programs for eczema into clinical development.

Capital signal: Large Series A rounds remain available for differentiated therapeutic platforms with clear development plans and strategic investor participation.

CHG Healthcare acquired KREWE Anesthesia, a staffing company focused on certified registered nurse anesthetists and managed anesthesia services. KREWE’s founders are expected to remain with the business.

Transaction signal: Anesthesia staffing remains a constrained labor category. The transaction shows how scaled workforce platforms can use acquisitions to add hard-to-source clinical specialties and deepen managed-services capabilities.

Teledyne Technologies agreed to acquire Varex Imaging in a transaction valued at approximately $1.1 billion. Varex supplies X-ray imaging components and related technologies used across medical and industrial applications.

Transaction signal: The deal reinforces strategic interest in imaging components and enabling technologies that sit inside larger diagnostic and medical-device ecosystems. Buyers can value differentiated installed technologies, engineering depth, and broad OEM relationships.

iRhythm completed its acquisition of VitalConnect on October 5, 2026. The original transaction was announced at approximately $288 million; closing consideration included $237.5 million cash, subject to adjustments, and up to 423,334 shares. Separately, iRhythm provided $10 million of working capital funding between signing and closing.

Transaction signal: The transaction reflects continued strategic consolidation around connected cardiac diagnostics and remote monitoring. Device platforms are pairing hardware, data, and workflow capabilities to broaden longitudinal patient monitoring.

Kyndryl completed its acquisition of Healthcare IT Leaders on September 14 for up to $350 million, including a contingent performance-based earnout. Healthcare IT Leaders provides enterprise IT consulting, managed services, and workforce solutions to hospitals and health systems.

Transaction signal: The acquisition deepens Kyndryl’s healthcare-specific applications, consulting, and managed-services capabilities. Domain expertise, implementation talent, and embedded health-system relationships can be strategically important alongside infrastructure and AI capabilities.

Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront plus potential milestone payments that could bring total consideration to approximately $1.32 billion. The transaction expands Jazz’s rare-disease pipeline.

Transaction signal: Large biopharma buyers continue to use targeted acquisitions to replenish pipelines and acquire differentiated clinical assets. Milestone-heavy structures also show how consideration can be tied to development and regulatory outcomes.

LifeMine Therapeutics raised $188 million in Series E financing to advance clinical development of an immunosuppressant for transplant patients.

Capital signal: Late-stage private capital can recapitalize development plans around priority clinical assets and extend runway through major milestones.

Health Catalyst completed the sale of Vitalware, its revenue-integrity and chargemaster technology business, to Med-Metrix. The transaction sharpens Health Catalyst’s focus on its healthcare intelligence platform while adding revenue-cycle capabilities to Med-Metrix.

Transaction signal: Portfolio pruning and capability-focused acquisitions are both active in healthcare technology. Revenue-cycle platforms continue to attract interest where software and services can improve reimbursement accuracy and operating performance.

Expedition Therapeutics raised an oversubscribed $115 million Series B to advance its lead DPP1 inhibitor through phase 2 development and support pipeline expansion.

Capital signal: Series B rounds are funding clinical execution while also giving companies capital to pursue additional assets and business-development opportunities.

Wellinks closed a $10 million Series B to expand its cardiopulmonary remote-patient-monitoring and predictive-care platform.

Capital signal: Strategic health-system participation can validate device-plus-data models that integrate monitoring with care delivery.

KKR agreed to acquire medical-device contract manufacturer Integer Holdings in an all-cash transaction valued at approximately $5.7 billion. Integer provides outsourced development and manufacturing services across high-growth medical-device categories.

Transaction signal: The take-private underscores sponsor interest in scaled medtech manufacturing platforms with entrenched OEM relationships, regulated production capabilities, and exposure to long-duration device programs.

Ratio Therapeutics raised a $70 million Series C to advance its radiopharmaceutical oncology program and scale manufacturing capabilities.

Capital signal: Radiopharma financings increasingly pair clinical development with manufacturing investment, making capital planning central to execution.

SoundHealth closed an oversubscribed $12.25 million Series A to support commercialization and development of its FDA-cleared AI-powered wearable for rhinitis and sleep-related breathing disorders.

Capital signal: Early-stage device financings can accelerate commercialization when a product has regulatory clearance and a defined clinical use case.

CoreMap closed a $37 million Series C led by Medtronic to accelerate its next-generation electrophysiology mapping platform for atrial fibrillation.

Capital signal: Strategic investment by a major device company can provide both capital and commercial validation for specialized medical technology.

Epitel raised a $26 million Series B to expand its FDA-cleared wireless EEG monitoring platform and AI-enabled seizure detection capabilities.

Capital signal: Connected medical devices that shift monitoring into ambulatory and home settings can attract capital when clinical utility and reimbursement pathways become clearer.

Included Health signed a definitive agreement to acquire Firefly Health, combining virtual care and navigation with Firefly’s clinically integrated health plan and advanced primary-care model.

Transaction signal: The transaction highlights continued convergence across employer health benefits, care navigation, virtual primary care and risk-bearing health-plan models.

Flourish Health raised a $26 million Series A to scale its intensive in-home care model for children and young adults with serious and complex mental-health needs.

Capital signal: Early-stage capital is still available for differentiated behavioral-health care models when funding is tied to measurable access, acuity and care-delivery expansion.

CARPL.ai raised a $10 million Series A to expand its radiology-AI platform, product development and global commercial footprint.

Capital signal: Imaging AI capital is increasingly tied to interoperability, deployment infrastructure and multi-market distribution rather than a single algorithm.

Crystalys Therapeutics raised $130 million in Series B financing to support late-stage clinical trials and potential commercialization preparation for dotinurad.

Capital signal: Investors may fund later-stage clinical and commercial preparation when an asset has meaningful de-risking or regulatory precedent.

Focus agreed to acquire GuideIT, expanding its healthcare technology platform with additional managed services, digital transformation, and IT consulting capabilities.

Transaction signal: Healthcare IT consolidation is extending across services, infrastructure, applications, and workflow modernization. Buyers are building broader platforms that can serve health systems across more of the technology stack.

TYBR Health raised a $30 million Series A to expand commercial access to its FDA-cleared B3 GEL System and fund additional orthopedic clinical studies.

Capital signal: Commercial-stage device companies may raise equity to broaden indications and scale adoption after initial regulatory clearance.

Knox Lane completed its acquisition of Cross Country Healthcare, taking the healthcare workforce solutions company private. Cross Country serves healthcare clients across travel nursing, allied health, physician staffing, and workforce management.

Transaction signal: The transaction reflects sponsor interest in scaled healthcare workforce platforms even as labor markets normalize. Technology, client density, workforce data, and diversified staffing modalities can support a broader value-creation thesis.

Dentalcorp acquired Northstar Dental Partners, a Florida dental group supporting 21 practices, marking Dentalcorp’s first expansion into the United States.

Transaction signal: Cross-border DSO expansion shows how scaled dental platforms can use acquisitions to enter new geographies while retaining local clinical leadership and practice-level relationships.

Tempus AI agreed to acquire Personalis for approximately $1.5 billion. Personalis develops molecular residual disease testing for cancer, and the transaction is intended to deepen Tempus’ oncology diagnostics and monitoring capabilities.

Transaction signal: Precision diagnostics are increasingly converging with healthcare data and AI platforms. Buyers are seeking proprietary assays, longitudinal datasets, and clinical workflow integration that can extend across the cancer-care continuum.

PAX Health acquired MAKRAF IME, a New Jersey provider of psychology and neuropsychology independent medical examinations with a statewide examiner network.

Transaction signal: The transaction highlights consolidation in specialized behavioral-health assessment and medical-legal services, where clinical credentials, referral relationships and statewide coverage can create strategic value.

Bunkerhill Health raised a $25 million Series B led by Khosla Ventures, bringing total funding to $55 million, to expand its agentic-AI platform inside health systems.

Capital signal: Hospital AI funding is increasingly tied to enterprise deployment and workflow adoption rather than stand-alone technology narratives.

RapidPulse closed an oversubscribed $48 million Series B to fund its pivotal thrombectomy study and pursue FDA approval.

Capital signal: Neurovascular device financings can bridge pivotal clinical work, regulatory milestones and future commercialization.

Neko Health raised $700 million in Series C funding ahead of the launch of its preventive-health clinics in the United States.

Capital signal: Large late-stage rounds can function as expansion capital for healthcare delivery models that combine physical infrastructure, diagnostics and technology.

AdvanCell raised a $315 million Series D to advance its prostate-cancer radiopharmaceutical program toward phase 3 and expand manufacturing capacity.

Capital signal: Large late-stage rounds can finance both pivotal development and specialized manufacturing infrastructure ahead of commercialization.

Guardian Dentistry Partners entered a definitive agreement for a strategic majority acquisition of Select Dental Management, which supports 38 locations across eight states and Washington, D.C.

Transaction signal: Majority DSO transactions continue to emphasize multi-state density, doctor alignment, infrastructure leverage and the ability to support future add-on growth.

410 Medical completed a $12 million growth round to scale commercial operations and support the next generation of its LifeFlow rapid-infusion platform.

Capital signal: Growth capital can support commercial expansion of established devices without requiring a control transaction.

Draig Therapeutics raised a $65 million Series B to advance a neurological pipeline led by a phase 2-stage candidate for major depressive disorder.

Capital signal: Neuropsychiatric drug-development capital can provide another financing avenue within the broader behavioral-health ecosystem while remaining distinct from provider-services M&A.

Chai Discovery raised a $400 million Series C to expand its AI-driven drug-discovery models after signing partnerships with major pharmaceutical companies.

Capital signal: AI-enabled drug discovery is attracting large growth rounds where technology has demonstrated real-world adoption by strategic pharmaceutical partners.

Sage secured a $35 million specialized debt facility from Stifel Bank to support expansion of its senior-care technology and Hardware-as-a-Service model.

Capital signal: Debt facilities can complement equity rounds when a healthcare technology company has identifiable growth investments, contracted customers or capital-efficient deployment needs.

Family & Children’s Services of Tulsa and Hope Community Services of Oklahoma City completed their merger, combining two large behavioral-health organizations serving communities across Oklahoma.

Transaction signal: Nonprofit behavioral-health combinations can create statewide scale, broaden access and consolidate administrative and clinical infrastructure even when the transaction does not involve a disclosed purchase price.

Celea Therapeutics raised $180 million in debut financing to take its antifibrotic candidate into a phase 3 study.

Capital signal: Large formation financings can effectively capitalize a new company around a later-stage asset and provide a non-M&A path for portfolio repositioning.

UnitedHealth Group disclosed that Optum completed its acquisition of Alegeus, a technology platform supporting health benefit accounts and consumer-directed healthcare programs.

Transaction signal: The acquisition reflects continued convergence between benefit administration, payments, consumer engagement, and healthcare technology. Scaled platforms with embedded payer and employer workflows remain strategically relevant.

Peak Rock Capital agreed to acquire Asembia, a specialty pharmacy services, technology, and network platform. The founding family is expected to retain a minority interest.

Transaction signal: Specialty pharmacy infrastructure remains attractive where technology, manufacturer services, pharmacy networks, and patient-access workflows create recurring relationships across the drug-delivery ecosystem.

Assort Health raised a $120 million Series C led by Menlo Ventures at a reported $1.2 billion valuation to scale AI agents used across the patient journey.

Capital signal: Large healthcare AI rounds are increasingly concentrated in platforms with broad workflow penetration and demonstrable provider adoption.

xCures closed a $46 million Series B to expand its platform for converting fragmented medical records into decision-ready clinical data.

Capital signal: Clinical-data infrastructure can attract growth capital when it addresses interoperability and workflow problems with clear enterprise use cases.

Ollin Biosciences raised a $330 million Series B to advance its ophthalmology candidate through a multi-trial phase 3 program.

Capital signal: Mega-rounds can concentrate capital in companies with compelling clinical data and expensive late-stage development programs.

H.B. Fuller made a recommended cash offer to acquire Advanced Medical Solutions Group, a tissue-healing and surgical products company, at an implied enterprise value of £715 million.

Transaction signal: The transaction shows a diversified industrial buyer deliberately increasing exposure to healthcare through regulated, higher-margin medical technologies. Specialized regulatory know-how and direct clinical channels can broaden strategic buyer interest beyond traditional device companies.

Deaconess Associations Incorporated agreed to acquire 31 home health and hospice agencies from HCA Healthcare, including 24 home health agencies and seven hospice agencies across eight states.

Transaction signal: Large home-based-care divestitures can quickly reshape geographic scale and referral density. Buyers may value local clinical teams, payer relationships and care-continuum positioning even when the seller is pruning noncore assets.

Cadence raised a $100 million Series C led by Spark Capital to scale AI-enabled chronic-care delivery for older adults with chronic disease.

Capital signal: Growth capital is flowing toward care models that pair clinical operations with automation and recurring payer or provider relationships.

Serapha Bio launched with a $230 million financing package consisting of a Series A and additional funding tied to its reverse-merger formation and licensed therapeutic program.

Capital signal: Company formation, asset licensing and capital raising can be combined into a single strategic transaction that sits between traditional venture financing and M&A.

Prosper AI raised a $30 million Series A led by Andreessen Horowitz to scale an AI platform spanning patient scheduling, insurance verification and billing.

Capital signal: Administrative AI is drawing growth capital where products can influence both patient access and provider revenue-cycle performance.

Abarca Health and LucyRx announced a strategic combination that is expected to create an independent pharmacy benefit manager serving more than 9 million members across commercial and government markets.

Transaction signal: PBM consolidation reflects the strategic importance of scale, claims infrastructure, pharmacy networks and technology as independent operators compete with vertically integrated incumbents.

WPS Health Solutions acquired Mavida Health, a digital mental-health provider focused on women and families across fertility, pregnancy, postpartum and other reproductive-life stages.

Transaction signal: The deal shows payers and health-services organizations moving upstream into targeted virtual care and behavioral-health delivery, creating convergence between insurance, digital health and provider services.

Abry Partners closed a $780 million oversubscribed continuation vehicle for Centauri Health Solutions, with Neuberger Private Markets and Apollo S3 serving as co-lead investors.

Capital signal: Continuation vehicles can provide liquidity to existing investors while allowing a sponsor to retain a healthcare asset and fund another phase of growth. This is directly relevant to recapitalization, shareholder-liquidity and structured-capital advisory.

Danaher completed its $9.9 billion acquisition of Masimo, adding patient-monitoring and pulse-oximetry technologies to a diagnostics portfolio that includes Radiometer.

Transaction signal: The transaction shows how strategic buyers can pursue device businesses that deepen hospital call points and create cross-selling opportunities across larger diagnostics portfolios.

Ethyreal Bio exited stealth with $101 million raised across Series A and Series B financings to advance a thyroid-eye-disease program into human testing.

Capital signal: Back-to-back early financings can capitalize a new therapeutic company through successive development milestones without a control transaction.

GT Medical Technologies raised an oversubscribed $100 million Series E to expand commercialization of GammaTile and fund additional clinical development in brain tumors.

Capital signal: Late-stage medtech financing can provide substantial non-control capital for commercial scale and clinical evidence generation.

CereVasc completed the initial closing of an $85 million Series C to support pivotal development and regulatory work for its minimally invasive eShunt System.

Capital signal: Series C capital frequently funds pivotal studies and regulatory milestones before commercial launch.

Ascension completed its acquisition of AMSURG, adding more than 250 ambulatory surgery centers to its care-delivery network and materially expanding its outpatient footprint.

Transaction signal: The transaction reflects health-system interest in ambulatory capacity and site-of-care diversification. Large ASC networks can provide geographic density, physician alignment, and lower-cost procedural settings outside traditional hospitals.

National HealthCare Corporation acquired five skilled nursing facilities in a transaction valued at approximately $50.5 million, expanding its post-acute care footprint.

Transaction signal: Skilled nursing transactions continue to be shaped by local density, reimbursement exposure, occupancy, labor, and real-estate structure. Strategic operators can use targeted acquisitions to deepen existing regional networks.

Advanced NanoTherapies closed an oversubscribed Series B of more than $31 million for its dual-drug balloon platform for coronary and peripheral artery disease.

Capital signal: Strategic and venture capital can fund development-stage devices as they move through breakthrough-designation and clinical pathways.

NewLimit raised a $435 million Series C to advance longevity-focused medicines toward clinical testing and expand its platform.

Capital signal: Large platform rounds can finance long-duration R&D programs when investors underwrite both a lead asset and the broader discovery engine.

Curio acquired Nora Mental Health, a multi-state franchise system of community-based mental-health clinics, bringing the clinical footprint and franchise infrastructure onto Curio’s behavioral-health platform.

Transaction signal: Franchise and multi-site behavioral-health models can attract strategic buyers when they provide replicable operations, local market expansion and a scalable provider network.

Kids Clinic India, which operates Cloudnine, agreed to combine with Apollo Health and Lifestyle’s Apollo Cradle and Apollo Fertility businesses, creating a platform with more than 55 centers while AHLL retains a 9.9% stake.

Transaction signal: Women’s health and fertility platforms can create scale through combinations that preserve seller rollover equity while consolidating brands, clinicians and center networks.

Nourish raised a $100 million Series C led by Menlo Ventures to expand its virtual metabolic-care model, provider network and AI tools.

Capital signal: Capital is supporting virtual-care platforms that combine clinical delivery, payer relationships and technology rather than relying on software-only business models.

9amHealth raised a $26 million Series B led by Define Ventures to expand its AI-enabled virtual specialty-care platform beyond cardiometabolic conditions.

Capital signal: Series B capital can fund category expansion once a virtual-care platform has established a core clinical model and employer or payer distribution.

A U.S. bankruptcy court approved the sale of CVS Health’s Omnicare long-term-care pharmacy business to GenieRx Holdings for $250 million in cash plus certain assumed liabilities.

Transaction signal: The transaction illustrates distressed and special-situations M&A in pharmacy services, where legal liabilities, customer continuity, working capital and operating turnaround requirements can materially affect deal structure.

Isomorphic Labs raised a $2.1 billion Series B to fund development of next-generation AI drug-design models and its broader discovery platform.

Capital signal: The size of the round highlights investor willingness to capitalize AI-driven life-sciences platforms at a scale historically associated with public markets or large strategic transactions.

Sanford Health and North Memorial Health signed a definitive agreement to combine in May and finalized the partnership on September 1, 2026. The organizations now operate as one nonprofit integrated health system under Sanford Health.

Transaction signal: Health-system combinations in 2026 increasingly reflect proactive capability building rather than distress alone. Regional scale, specialty access, capital needs, and operating resilience remain central strategic considerations.

Amulet Capital Partners announced an investment in TFP Fertility Group, a European fertility-services platform. The transaction supports continued expansion of the group’s network and clinical capabilities.

Transaction signal: Fertility remains a specialized provider-services segment where scale, physician recruitment, laboratory quality, referral networks, and patient conversion can shape platform value and sponsor interest.

Enzo Health raised a $20 million Series A led by N47, bringing total funding to $26 million, to expand its AI-driven operating platform across home health, skilled nursing and hospice.

Capital signal: Home-based care technology can attract capital when it addresses referral, clinical documentation, compliance and reimbursement workflows across fragmented post-acute providers.

Carlyle acquired Knack RCM and EqualizeRCM and combined the businesses to create a scaled revenue-cycle management platform with technology-enabled and AI-oriented capabilities.

Transaction signal: Sponsor-backed healthcare technology platforms are increasingly being built around measurable workflow automation and labor productivity. RCM remains a particularly active area because technology can directly affect cash conversion and operating leverage.

LEO Pharma agreed to acquire Replay for $50 million upfront plus additional milestones and tiered royalties, adding Replay’s HSV-based gene-therapy platform for rare genetic skin disease.

Transaction signal: Smaller strategic biotech acquisitions can pair modest upfront consideration with contingent economics to transfer platform control while preserving upside for sellers if development succeeds.

Coultreon Biopharma raised a $125 million Series A after rebranding from Onco3R Therapeutics to advance autoimmune-disease assets acquired from Galapagos.

Capital signal: New-company financings can provide capital for teams to advance assets carved out or redirected from larger pharmaceutical portfolios.

beBright acquired Pediatric Dentistry of Shreveport-Bossier, adding six locations, 10 pediatric dentists and more than 100 staff members in Louisiana.

Transaction signal: Specialty dental platforms can use larger affiliations to add clinician density, regional scale and complementary pediatric or orthodontic capabilities while preserving local provider relationships.

Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, including an upfront payment and contingent clinical and regulatory milestones tied to Ajax’s hematology pipeline.

Transaction signal: Biopharma M&A continues to use milestone-based structures where a strategic buyer seeks control of a promising clinical asset but part of the consideration remains dependent on development outcomes.

Sun Pharmaceutical Industries signed a definitive agreement to acquire Organon for $14.00 per share in cash, valuing the women’s-health and biosimilars company at $11.75 billion in enterprise value.

Transaction signal: Large pharmaceutical acquisitions continue to be driven by portfolio diversification, global commercial scale, women’s-health franchises and the need to strengthen growth assets ahead of patent and pipeline transitions.

IKS Health agreed to acquire TruBridge, a healthcare technology and services company serving community and rural healthcare organizations, for $26.25 per share.

Transaction signal: The transaction extends consolidation across healthcare technology, revenue-cycle, and operational support services. Community and rural providers remain important customers for platforms that can spread technology and administrative capabilities across smaller organizations.

Cala Health secured $50 million in growth capital from Trinity Capital to support commercial expansion of its FDA-cleared wearable tremor therapy.

Capital signal: Growth capital can provide an alternative to a traditional equity round for commercial-stage healthcare businesses with established products and revenue.

ModMed acquired Bonsai Health, adding AI-powered patient engagement and workflow capabilities to its specialty healthcare technology platform.

Transaction signal: AI-enabled patient engagement is moving from standalone feature to platform capability. Acquirers are looking for technologies that can improve access, conversion, scheduling, and front-office productivity within existing clinical workflows.

Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront plus milestone payments tied to Kelonia’s in vivo CAR-T technology.

Transaction signal: Milestone-heavy biotech acquisitions can bridge valuation gaps around early clinical assets while giving strategic buyers control of differentiated platforms with potentially large commercial upside.

Pulnovo Medical completed an oversubscribed $100 million strategic financing and entered a commercial agreement with lead investor Medtronic.

Capital signal: Strategic financings can combine capital with future commercialization pathways, creating alternatives to an outright sale.

Beeline Medicines launched with a $300 million Series A and a portfolio of autoimmune programs licensed from Bristol Myers Squibb.

Capital signal: Large formation rounds can pair experienced management, licensed assets and institutional capital to create a new standalone pharmaceutical platform.

Endovascular Engineering raised $80 million in Series C capital to support commercialization of its Hēlo thrombectomy platform for pulmonary embolism.

Capital signal: Commercialization-stage financings can provide substantial growth capital while preserving independence ahead of broader strategic alternatives.

ESO acquired d2i, adding analytics and emergency-care intelligence capabilities across fire, EMS, and health-system workflows.

Transaction signal: Emergency-care technology is consolidating around connected data, benchmarking, and operational intelligence. Platforms that bridge pre-hospital and hospital data can create differentiated workflow and analytics value.

Gilead Sciences entered a definitive agreement to acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestone payments, adding a next-generation antibody-drug-conjugate platform.

Transaction signal: Strategic pharma buyers continue to use acquisitions to secure differentiated oncology technologies, with contingent consideration helping allocate development and commercialization risk.

Insight Health raised an $11 million Series A led by Standard Capital to scale voice-first clinical agents that automate referral, intake and scheduling workflows.

Capital signal: Workflow-specific AI companies are attracting early-stage capital when they can demonstrate labor savings inside clinical organizations.

Gyde acquired Avid Health, expanding its technology-enabled member engagement and benefits-navigation capabilities.

Transaction signal: Payer and benefits technology continues to converge around navigation, engagement, and consumer experience. Embedded relationships with plans and members can create strategic value even when broader managed-care M&A is selective.

IKS Health completed an acquihire of ThinkDTM, adding AI and technology talent to support its healthcare operations and digital transformation capabilities.

Transaction signal: Healthcare technology transactions are not limited to full platform acquisitions. Talent-led transactions can accelerate AI capability building where specialized engineering and healthcare-domain expertise are scarce.

eMed raised $200 million in Series A funding at a reported valuation above $2 billion to support its telehealth, GLP-1 management and population-health platform.

Capital signal: Large early institutional rounds can fund rapid scaling when a healthcare company has already built distribution, enterprise relationships and a differentiated operating model.

Endogenx raised $138 million in Series C financing for its non-thermal pulsed-electric-field platform targeting Type 2 diabetes.

Capital signal: Large clinical-stage device rounds show that investors will fund differentiated therapeutic technologies through capital-intensive development programs.

Gilgamesh Pharma raised a $60 million Series A for a portfolio of neuropsychiatric therapeutics after a prior licensing transaction led to a corporate spinout.

Capital signal: Capital raises can be part of a broader strategic restructuring in which assets are licensed, companies are separated and new equity is raised around the retained pipeline.

The Chartis Group acquired Leap AI, adding artificial-intelligence capabilities to its healthcare advisory and transformation platform.

Transaction signal: Healthcare services firms are increasingly buying AI capabilities rather than relying only on partnerships or internal development. Transactions that combine advisory relationships with proprietary technology can broaden both delivery capacity and recurring revenue potential.

Definity raised a $7 million Series A led by Accrete Health Partners to scale its vendor-neutral workforce-management platform for health systems.

Capital signal: Healthcare labor remains a strategic pain point, creating capital demand for technology that improves contingent-labor visibility, sourcing and workforce utilization.

Aveanna Healthcare agreed to acquire Family First Homecare, expanding its pediatric home-care and private-duty nursing footprint.

Transaction signal: Home-based care consolidation continues to center on clinical labor density, referral relationships, payor mix, geographic coverage, and the ability to recruit and retain specialized caregivers.

Universal Health Services agreed to acquire Talkspace in a transaction with an enterprise value of approximately $835 million, combining a scaled behavioral-health operator with a digital mental-health platform.

Transaction signal: The deal illustrates convergence between physical care networks and digital behavioral-health access. Strategic buyers can value technology platforms that extend reach, diversify channels, and create longitudinal patient relationships.

Sage raised a $65 million Series C led by Goldman Sachs Alternatives to expand its care platform and AI-enabled monitoring tools for senior living and skilled nursing.

Capital signal: Late-stage healthcare technology capital is increasingly tied to measurable deployment within care settings and to solutions that address labor and safety constraints.

Community Health Systems agreed to sell four Arkansas hospitals to Freeman Health System for approximately $112 million.

Transaction signal: Hospital portfolio rationalization remains an important source of transaction activity. Regional buyers can use divestitures to build scale while sellers redeploy capital toward core markets and balance-sheet priorities.

Surgery Partners acquired Preferred Vascular Group, an operator of eight ambulatory surgery centers focused on specialty dialysis-access procedures in Georgia and Ohio.

Transaction signal: ASC buyers continue to pursue specialty platforms where procedure migration, physician alignment and focused clinical capabilities can support durable growth and attractive site-of-care economics.

MUSC Health acquired Palmetto Primary Care Physicians, expanding its primary-care network and physician footprint in South Carolina. Public reporting placed the transaction at approximately $111 million.

Transaction signal: Health systems continue to invest in physician networks that can deepen referral capture, support population health, and expand ambulatory access. Primary-care density can be strategically important even when individual practice economics are modest.

Omni Family of Services acquired JusticeWorks YouthCare, expanding community-based behavioral and child-and-family services.

Transaction signal: Behavioral-health platforms continue to expand through adjacent community-based services where referral relationships, state programs, clinical workforce, and local operating density can support growth.

DoseSpot and Arrive Health merged to form Interra Health, combining e-prescribing and medication-access technology. Bain Capital Tech Opportunities became the majority owner of the combined business.

Transaction signal: Medication workflow platforms are combining prescribing, affordability, and access capabilities into broader infrastructure. Sponsor support can accelerate product integration and distribution across provider and pharmacy networks.

Altru Health System completed the transfer of CHI St. Alexius Health Devils Lake, adding the North Dakota hospital to its regional health-system network.

Transaction signal: Regional hospital transactions can be driven by local sustainability, access to capital, clinical integration, and the ability to preserve services in smaller markets.

Alignment Healthcare entered into a three-year $200 million senior secured revolving credit facility with Citibank and other lenders, providing liquidity that can be used for permitted acquisitions and other corporate purposes.

Capital signal: Revolving credit capacity gives healthcare companies acquisition dry powder and liquidity without requiring an immediate equity raise, making debt placement and capital-structure planning part of the broader transaction landscape.

Asahi Kasei agreed to acquire German antiviral drug developer AiCuris in a transaction reported at approximately €780 million.

Transaction signal: Pharma buyers continue to target specialized biotech pipelines that can add therapeutic depth and reduce reliance on internal R&D alone. Cross-border transactions remain an important part of pipeline replenishment.

GSK agreed to acquire 35Pharma for approximately $950 million in cash, adding clinical-stage assets to its development pipeline.

Transaction signal: Targeted biotech acquisitions remain an important mechanism for large pharmaceutical companies to add differentiated programs and expand future growth options.

Slate Medicines raised a $130 million Series A to advance next-generation migraine therapies, including a lead monoclonal antibody licensed from DartsBio Pharmaceuticals.

Capital signal: Large Series A financings can establish a new therapeutic platform around in-licensed assets and fund the first clinical milestones.

Kinderhook Industries agreed to acquire Enhabit in a take-private transaction valued at approximately $1.1 billion enterprise value. Enhabit operates home health and hospice locations across the United States.

Transaction signal: The transaction highlights continued sponsor interest in scaled home-based care despite reimbursement and labor complexity. Branch density, clinical outcomes, referral relationships, and operating discipline remain central to underwriting.

Hims & Hers Health agreed to acquire Eucalyptus in a transaction valued at up to approximately $1.15 billion, expanding its global consumer-health and digital-care platform.

Transaction signal: Consumer health platforms are using M&A to add geographic reach, clinical capabilities, and new care categories. The transaction shows how digital-health value can depend on brand, patient acquisition, care delivery, and recurring relationships—not software alone.

Center for Social Dynamics acquired New Mexico-based Behavior Change Institute, expanding autism diagnostics, ABA therapy and behavioral-health services in the Southwest.

Transaction signal: Autism-services platforms continue to use M&A to add clinical capacity, geography and specialized diagnostic capabilities. Provider quality, payer relationships and clinician recruitment remain central underwriting considerations.

Prime Healthcare Foundation became the sole corporate member and parent of Central Maine Healthcare, completing a nonprofit health-system combination.

Transaction signal: Hospital affiliations can use nonprofit structures and membership transfers rather than conventional acquisition consideration. Governance, capital commitments, community obligations, and service continuity are often as important as headline purchase price.

Talkiatry announced $210 million of Series D financing led by Perceptive Advisors, with participation from existing and new equity investors and a debt facility from Banc of California.

Capital signal: The financing shows how scaled behavioral-health platforms can combine late-stage equity and debt to fund growth, technology investment and potential public-market readiness.

KeyCare raised $27.4 million in new financing led by HealthX Ventures to scale its Epic-integrated virtual-care platform for health systems.

Capital signal: Strategic health-system investors and specialized healthcare funds can provide growth capital to platforms that deepen rather than fragment existing clinical workflows.

Waters completed its combination with Becton Dickinson’s Biosciences & Diagnostic Solutions businesses. Based on Waters’ closing share price before completion, BD said the separated business was valued at approximately $18.8 billion.

Transaction signal: The Reverse Morris Trust combination created a much larger life-sciences and diagnostics platform with exposure to recurring regulated testing workflows. Portfolio separation and scale-building remain important strategic themes in diagnostics.

Eli Lilly agreed to acquire Orna Therapeutics in a transaction valued at up to approximately $2.4 billion, adding circular RNA technology and development programs.

Transaction signal: Large pharmaceutical companies continue to use M&A to acquire novel therapeutic modalities and platform technologies. Transactions around differentiated science can carry meaningful contingent value tied to development progress.

Choice Health at Home announced acquisitions of Cy-Fair Health Care, Alliant Home Health, Palliative and Hospice Care, and Senior Nannies Private Care, expanding across the in-home care continuum.

Transaction signal: Multi-company home-care acquisitions show the value of building an integrated continuum across skilled home health, hospice, palliative care and private-duty services while increasing regional density.

Community Health Systems completed the sale of three Pennsylvania hospitals to Tenor Health Foundation for $33 million in cash plus a $15 million note.

Transaction signal: Hospital divestitures can involve structured consideration and nonprofit buyers focused on maintaining local operations. Transaction economics often reflect facility performance, capital needs, and community continuity considerations.

Sword Health acquired Kaia Health for approximately $285 million, combining two digital musculoskeletal care platforms and expanding Sword’s employer and health-plan reach.

Transaction signal: Digital health consolidation is increasingly about category leadership, distribution, and the economics of scaled patient engagement. Buyers are combining overlapping platforms to deepen clinical pathways and reduce fragmented customer procurement.

Premier Care Dental Management acquired Blank Dental Group, a three-location dental practice in Ohio, continuing its regional expansion strategy.

Transaction signal: Smaller add-on acquisitions remain an important part of DSO platform building because they can add local density, provider relationships and operating leverage without requiring a large platform transaction.

Boston Scientific agreed to acquire Penumbra in a transaction valued at approximately $14.5 billion, significantly expanding its neurovascular and thrombectomy portfolio.

Transaction signal: The transaction is one of the largest medtech deals of 2026 and illustrates strategic willingness to pay for scaled, high-growth clinical franchises with differentiated device portfolios and strong procedure exposure.

Inquis Medical closed a $75 million Series C to accelerate U.S. commercial expansion of its thrombectomy system and advance its product pipeline.

Capital signal: Series C financing can support the transition from regulatory achievement to nationwide commercial scale.

Spiro Medical closed a $67 million Series A to develop an implantable pulmonary neuromodulation system for asthma and fund U.S. clinical and regulatory work.

Capital signal: Large Series A rounds can finance capital-intensive device development when a novel therapeutic platform requires multi-year clinical and regulatory execution.

RWJBarnabas Health and Englewood Health announced a definitive agreement for Englewood Health to join the larger New Jersey health system while maintaining its local identity.

Transaction signal: Independent health systems are increasingly evaluating partnerships from a position of strategic planning rather than waiting for distress. Clinical capabilities, capital access, physician alignment, and regional scale can drive these combinations.